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CHAPTER 1 “DENDRIMER−BASED NANODEVICES” 
1.1 Dendrimers in Nanomedicine: The Rationale 
Due to their unique properties dendrimers have exceptional potential for the application in 
the emerging field of nanomedicine. The goal of nanomedicine is to control and manipulate 
biomacromolecular constructs and supramolecular assemblies such as proteins, DNA/RNA, 
viruses, cellular lipid bilayers, cellular receptor sites and antibody variable regions that are 
critical to living cells in order to improve the quality of human health. The nanotherapeutics and 
diagnostic devices will allow a deeper understanding of human life and illnesses such as cancer, 
cardiovascular disease, genetic disorders, and trauma.1 Detection of a disease in its earliest stage 
is the ultimate goal.  
Dendrimers are polymers having highly branched structures and globular shapes with the 
nanosize ranging from 2 to 10 nm. Due to their exceptional structural properties such as 
monodispersity, controllable size and structure, modifiable surface functionalities, and 
multivalency they have become prominent synthetic macromolecules in the field of biomedical 
science. Dendrimers are widely utilized as drug delivery systems, antiviral agents and  magnetic 
resonance imaging contrast agents.2-7 In the past decades dendrimers have been investigated as  
novel diagnostic nanodevices.8,9 They have been utilized in dip-pen nanolithography,10 DNA and 
protein arrays,11,12 nanocatalyst-based electro-chemical immunosensor,13 biosensor-based on 
dendrimer encapsulated Pt nanoparticles14 and regenerable affinity biosensing surfaces.15 
Research in antibody-based diagnostics has been focused on improving the specificity and 
sensitivity of immunoassay techniques.  The most important steps in the development of 
immunosensors are the immobilization of antibodies onto a substrate at high density with 
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uniform distribution, retaining their specific antigen-binding activities, maintaining accessibility 
to the antigens,16 and minimizing nonspecific adsorptions of extraneous cellular proteins onto the 
modified surfaces, which can reduce the sensitivity during detection steps.  Based on their 
properties, dendrimers could play an essential role in each of these steps. Dendrimers can form 
stable, dense, well-organized, and close-packed arrays on substrate surfaces and they have ability 
to incorporate multiple branch ends available for conjugation reactions.8 Recently Kannan’s 
group has reported a dendrimer based ELISA assay for IL-6 and IL-1β cytokines capture that are 
found in infected intraamniotic fluid.17 The dendrimer modified plate provides assays with 
significantly enhanced sensitivity, lower nonspecific adsorption, and  significantly higher  
detection limits compared to traditional ELISA. 
Controlled delivery of drugs can sustain blood level of the drug over a long period of 
time, decrease side effects, and lead the drug through the body without degradation, increase 
drug solubility, and decrease dose.  The functional surface groups on dendrimers can affect their 
physicochemical properties. It is known that these functional groups make dendrimers very 
hydrophilic and highly water soluble.18 Drug molecules can be either encapsulated, complexed, 
or covalently attached to the dendrimers through their functional groups.19,20 The most common 
covalently linkage of the drugs to surface functional groups of dendrimers can be achieved by a 
coupling reaction through the ester or amide bonds. If the drug does not have a reactive group, a 
spacer or linker molecules are very often used to provide the drug with reactive group, which is 
required for coupling reaction with dendrimer. These ester or amide bonds, can be cleaved either 
hydrolytically or enzymatically.21 The drug release due to hydrolysis will be governed by the pH 
of the media and ester bonds are more liable towards the hydrolysis compared to amide bonds.22 
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The study has showed that ester linked conjugates in human plasma can be hydrolyzed by 
esterase enzymes, while amide bonds are relatively  stable.23,24 Disulfide bonds have also been 
demonstrated to be cleaved in the presence of intracellular glutathione (GSH).25 Targeting 
ligands can be linked to the functional groups of dendrimers too, and used for targeted drug 
delivery.20 
The key issues in the design of dendrimer-drug nanodevices include improving drug 
payload, overcoming cytotoxicity especially in the case of cationic dendrimers, understanding 
the mechanism and dynamics of intracellular transport, and engineering of the drug release at the 
appropriate tissue. This can be achieved by optimizing biodistrubution, passive targeting – 
mediated via EPR (enhanced permeability retention) effect involving organ-specific targeting, 
and active targeting – receptor-mediated cell-specific targeting involving receptor-specific 
targeting groups.1,22 Cellular uptake of dendrimers is affected by their size,  type and the charge 
of surface groups.26,27 Although there has been a significant success of attaching a multiple drug 
molecules on dendrimers, optimal release of drugs is still a challenge. Presence or absence of 
linker can greatly affect the drug release from dendrimers.21 High stability of the conjugate or 
release of the drug before reaching its target will make the dendrimer-drug-delivery system 
ineffective. 
1.2 Introduction to Dendrimers 
Dendrimers are well-defined polymeric macromolecules having nanometer size and 
unique properties. The structure of dendrimers consists of a repetitive sequence of monomers, 
called branching units (dendrons). These units are growing from a core in a radial iterative 
fashion giving rise to higher generations (Figure 1). Beside the branching units, dendrimers 
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always have core units, and surface groups located at their peripheries.28 Due to controlled step 
by step synthesis dendrimers are nearly monodisperse architectures  (polydispersity indexes 
close to 1),29 in contrast to traditional polymers. One of the most attracting aspects reletad to 
dendrimers is that it is relatively easily to control their size, composition, and physicochemical 
properties in a very precise manner.  
 
Figure 1. Schematic representation of generation four hydroxyl PAMAM dendrimer.  
 
This type of molecules were first time synthesized by Vögtle in 1978 and called 
cascade.30 The synthesis involves two steps; first step is an exhaustive Michael-type addition of 
acrylonitrile to an amine, and second step is reduction of nitrile groups to primary amines. These 
steps could be theoretically repeated to give highly branched macromolecules, but there are 
difficulties due to loss of substrate catalytic activity and poor yields. In early 1980s Denkewalter 
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and co-workers patented the synthesis of polylysine dendrimers.31 Then in 1985, similar  type of 
molecules were synthesized independently by Newkome and Tomalia groups.32,33 Newkome 
named his molecules as arbosols, while Tomalia dendrimers, based on two greek words, 
‘dendros’ meaning tree and ‘meros’ meaning part.  
1.3 Synthesis of Dendrimers 
There are two approaches for dendrimer synthesis. First approach is called divergent 
method that was developed by Tomalia. Tomalia synthesized poly(amidoamine) (PAMAM) 
dendrimers by this method, in which the growth of dendrimer starts from a core as the root and 
goes outward building up generation by generation. The second approach, developed by Hawker 
and Fréchet, is convergent method, which proceeds from the dendron surface inward to a 
reactive focal point at the root.  
1.3.1 Divergent Method 
The name of divergent method originates from the way how dendrimers grow starting 
from the core and going outwards, i.e. diverging into space (Figure 2). The synthesis consists of 
two steps: the core is reacted with two or more moles of reagent containing at least two protected 
branching sites, followed by removal of the protecting groups. The subsequent deprotected 
reactive sites lead to the zero generation dendrimers. This process can be repeated until the 
dendrimer with desired size and nuber of terminal groups is obtained. Usually ethylene diamine, 
ammonia, or cystamine may be used as cores.34 relatively large dendrimers can be prepared using 
this method. However, the isolation and characterization can be hard due to incomplete growth 
steps and side reactions.  
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Figure 2. Dendrimer synthesis by divergent growth method [Adopted from Ref. 28] 
 
1.3.2 Convergent Method 
In response to the disadvantages of divergent method convergent method was developed 
by Hawker and Fréchet in 1990 (Figure 3).35 The synthesis involves two steps: the first is a 
reiterative coupling of protected/deprotected branching units to obtain a focal point 
functionalized dendron and the second is the reaction of several dendrons leading to formation of 
dendrimer. Basically, the convergent growth starts at the surface of the dendrimer and proceeds 
inwards by progressively linking surface units with other monomers. When the growing blocks, 
called dendrons, are large enough, several of them are attached to an appropriate core to give a 
complete dendritic structure. Compared to divergent method the convergent method requires 
only two simultaneous reactions for any-adding step, it has lower number of side reactions and 
purification of dendrimers is simpler. 
 
 
Figure 3. Dendrimer synthesis by convergent growth method [Adopted from Ref. 28] 
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1.4 Properties of Dendrimers 
Dendrimers have crucial properties required for fabrication of the synthetic nanostructures 
with size, shape, surface chemistry similar to nanobiological constracts. They are nearly 
monodisperse, nanoscale size, well-defined molecular structures. Their size is similar to globular 
proteins. Generation 4 PAMAM dendrimer has size comparable to cytochrome c (4 nm), 
generation 5 PAMAM dendrimer has size comparable to hemoglobin (5 nm), and so on. Based 
on their systematic, dimensional length scaling, narrow size distribution, and biomimetic 
properties dendrimers are like ‘artificial proteins’.36 On the contrary to proteins, dendrimers are 
known to be robust, covalently fixed, three-dimensional structures possessing both solvent-filled 
interior hollowness and defined surface functionality. 
Dendrimers are multivalent ligands due to presence of high number of reactive terminal 
groups. Dendritic scaffolds, compared to the other multivalent ligands such as polymers, 
proteins, and liposomes, exhibit advantageous controllable synthesis pathway. They have the 
ability of linking different chemical moieties on the surface, and in the interior. Dendrimer 
surface may be functionally designed to enhance or reduce trans-cellular, epithelial or vascular 
biopermeability. They also have a void space within the structure of the scaffold suitable for 
encapsulation of small-molecule drugs, metals (e.g. gold, silver) or signalling groups. These 
features make dendrimers ideal drug carriers with high drug payload capacities.37 Complexation 
of the drug to the dendrimers can lead to enhanced permeation and retention (EPR) of the drug in 
the targeted sites.1 
The properties of dendrimrs are tailored by the functional groups on their surface. They can 
be water-soluble when their end-groups are hydrophilic such as hydroxyl, amino, and carboxyl 
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groups as seen in PAMAM dendrimers. Dendrimer conformations are determined by dendrimer 
growth, the nature of building blocks, end-group functionalities, and the external environment.29 
Hydrogen bonding of terminal groups makes outer shell of dendrimers more rigid. Conforamtion 
of dendrimers stricktly depends on pH. At low pH (~3), all primary amine groups of PAMAM 
dendrimers are protonated leading to an extended conformation due to electrostatic repulsion 
between the positively charged NH3+   groups. At neutral pH back folding occurs which is due to 
the hydrogen bonding between the uncharged tertiary amines in the interior and the positively 
charged surface amines. At basic pH the dendrimer is completely neutralized and repulsive 
interactions between the wedges and end-groups reach a minimum leading to a conformation 
with a higher degree of back folding so dendrimer acquires a more spherical (globular) structure. 
The conformation of dendrimers is also affected by the polarity of the solvent as well as the ionic 
strength (high concentration of salts).28 
In order to use dendrimers for drug design or as drug delivery devices in vivo, dendrimers 
have to be non-toxic, non-immunogenic (except for vaccines), and able to cross biobarriers 
(biopermeable) such as, the intestines, the blood–tissue barriers, cell membranes, and so on. 
They also have to be capable of staying in circulation for the time needed to target specific 
organs and exhibit clinical effects. The cytotoxicity of dendrimers is related to their size and 
surface groups which are directly interacting to cells’ membrane. It has been reported that 
cationic dendrimers show heamolitic and cytotoxic effect at even relatively low concentration, 
while anionic and hydroxyl terminated dendrimers are not toxic. The studies showed that amino-
terminated PAMAM dendrimers are weakly immunogenic, which can be eliminated by 
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pegylation with polyethylene glycol (PEG) chains. It also extends dendrimers lifetime in the 
blood stream compared to unmodified dendrimers.38 
1.5 PAMAM Dendrimers 
Polyamidoamine (PAMAM) dendrimers were synthesized by Tomalia.33 They are known 
to be first commercialized dendrimers family, which are the most extensively characterized and 
widely used. PAMAM dendrimers have ethylene diamine (EDA) core and an amidoamine repeat 
branching structure. They are synthesized via Michael addition of amino groups of EDA with 
methyl acrylate, followed by amidation of the resulting esters with EDA, and generation 0 is 
formed (Figure 4). A repetition of these two synthetic steps adds another layer of branching units 
and produces next generation. The size of dendrimer grows linearly in diameter as a function of 
added generations, approximately 1 nm per generation (Table 1).  Each new generation also 
doubles the number of terminal groups and approximately doubles the molecular weight of the 
previous generation. Figure 4 shows the synthesis of amine (NH2) terminated PAMAM 
dendrimers that are cationic; however there are also neutral hydroxyl (OH) and anionic carboxyl 
(COOH) terminated PAMAM dendrimers. Due to half completion of the monomer addition the 
carboxyl terminated dendrimers are called half generations.  These active terminal groups make 
dendrimers multivalent and they can be used to covalently attach several drug molecules, 
targeting groups, and other agent to the periphery of dendrimers in a well-defined manner. To 
avoid sterical hindrance and to provide drug with reactive group, a variety of spacer molecules 
can be linked to the drug and as such used for conjugation reaction with dendrimers. The 
presence of hydrophilic terminal groups makes dendrimers highly water soluble. The solubility 
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increases with the generation number; the higher generation, the higher number of terminal 
groups, leads to increased surface charge and polarity. 
 
Figure 4. Synthesis of PAMAM dendrimer by Tomalia et al33 
 
Table 1. Physicochemical characteristics of amine terminated PAMAM dendrimers 
Generation 
 
Number of surface 
groups 
Molecular weight 
 
Diameter (nm) 
 
0 4 517 1.5 
1 8 1,430 2.2 
2 16 3,256 2.9 
3 32 6,909 3.6 
4 64 14,215 4.5 
5 128 28,826 5.4 
6 256 58,048 6.7 
7 512 116,493 8.1 
8 1024 233,383 9.7 
9 2048 467,162 11.4 
10 4096 934,720 13.5 
11 
 
1.6 Research Objectives 
Over the past several decades, a great number of dendrimer structures with various 
chemical compositions have been developed and investigated for a variety of applications in 
physics, chemistry, biology, and medicine. Among them, poly(amidoamine) (PAMAM) 
dendrimers are the most extensively characterized and widely used. Even though many different 
surface end functionalities are available on these dendrimers, -NH2, -OH, and -COOH end 
groups are the most commonly studied. Of these, the hydroxyl-terminated ethylenediamine core 
generation 4 poly(amidoamine) dendrimers (G4-OH PAMAM) that are  highly biocompatible, 
and have low protein interactions are explored here  as  vehicles for targeted intracellular drug 
delivery.  The overall scientific goal of this research is to tailor the G4-OH PAMAM dendrimer 
surface, linking chemistry, and other physicochemical properties for enabling covalent linking 
with drugs, imaging agents and antibodies, to impact the improved functionality in the resultant 
nanodevices. Two specific goals are pursued: (1) development of G4-OH PAMAM dendrimer – 
drug nanodevices, and (2) development of G4-OH PAMAM dendrimer-based multipurpose 
novel diagnostic platforms. As mentioned dendrimers have multiple terminal functional groups 
available for further conjugation between dendrimer functionalities and guest molecules. The 
most common covalent linkages of the guest molecules to surface functional groups of 
dendrimers are ester or amide that are usually obtained by coupling reactions. Recently our 
group has been used disulfide bond to link the drug molecules to dendrimers.25 In the case of the 
development of dendrimer-drug nanodevices choosing the right linkage and/or putting the proper 
spacer between the dendrimer and drug molecules the drug payload can be increased, the 
cytotoxicity especially in the case of cationic dendrimers will be avoided, and the drug will 
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release at the appropriate tissue. The development of dendrimer-based diagnostic nanodevices 
includes dendrimer-linked antibody assays. The design involves various linking chemistries 
between solid support and dendrimer, and between dendrimer and antibody such as amide, 
sulfide, and hydrazone bonds. Introducing the dendrimer as a spacer between antibody and solid 
support reduces non-specific interactions between immobilized antibody and analyte which will 
improve the detection limits. 
In this thesis four chapters are discussed. In Chapter 1 an overview of dendrimers 
evolution and their role in nanomedicine is summarized. The synthesis, characterization, and in 
vitro study of dendrimer-Erythromycin (D-EM) nanodevice for sustained treatment of orthopedic 
inflammation are described in Chapter 2. In Chapter 3 the G4-OH PAMAM dendrimer is used to 
develop an immunoassay for detection of TNF-α cytokine.  Chapter 4 describes the synthesis, 
characterization, and in vitro studies of dendrimer-allopregnanolone isomer and dendrimer-
allopregnanolone nanodevices for traumatin brain injury (TBI) treatment. 
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CHAPTER 2 “SYNTHESIS, CHARACTERIZATION, DRUG RELEASE PROFILE, 
AND IN VITRO EFFICACY OF PAMAM DENDRIMER-ERYTHROMYCIN 
NANODEVICES”  
2.1 Abstract 
Erythromycin (EM), an antibiotic that has been used for infectious diseases, is now 
gaining attention because of its novel anti-inflammatory effects. A dendrimer-EM nanodevice is 
explored for sustained treatment of orthopedic inflammation. To sustain pharmacological 
activity, EM has been conjugated to poly(amidoamine) dendrimer (PAMAM) through an ester 
bond. Hydroxyl-terminated poly(amidoamine) dendrimer (G4-OH) was reacted to a protected 
amine linker followed by deprotection  to obtain a bifunctional dendrimer that contains 10-15 % 
amine groups. EM was modified to EM-glutarate then conjugated to the bifunctional dendrimer 
through an amide bond. The cytotoxicity and activity of this EM-dendrimer conjugate was 
evaluated on RAW 264.7 cells in vitro by lactate dehydrogenase (LDH) assay and nitric oxide 
(NO) assay, respectively. From LDH assay dendrimer-EM conjugate and free EM were found to 
be non-cytotoxic within the dose range 0.1-1 µg/mL after 48 hours.  Dendrimer-EM conjugate 
showed significant nitrite inhibition activity, reducing the nitrite levels by 42 % as compared to 
those in untreated cells. Dendrimer-EM conjugate has better efficacy than free EM for dose 
concentration of 1-10 µg/mL. The improvement in the in vitro efficacy of EM by dendrimer 
conjugation was the strongest within the dosage range of (5-10) µg/mL. The zone of inhibition of 
dendrimer-EM conjugate on bacterial growth at different concentrations showed similar activity 
compared to free EM treatment with equivalent dose. Furthermore, free dendrimer did not show 
any effect of bacterial inhibition at the concentration up to 0.2 mg/mL.  
14 
 
2.2 Introduction 
Dendrimers are polymers with highly branched structures and globular shapes with the 
size range 2-10 nm. Due to their properties such as monodispersity, controllable size and 
structure, tailorable surface functionality, and multivalency, they are extensively investigated for 
various biomedical applications2,36 such as drug delivery systems,5-7 antiviral agents, and as 
magnetic resonance imaging contrast agents.3,4 PAMAM dendrimers have also been studied in 
isolation as topical antibacterial agents to treat intrauterine infections.39 In the past decades 
dendrimers have been investigated as novel diagnostic nanodevices.8,9 Recently our group has 
reported a dendrimer based ELISA assay for IL-6 cytokine detection that is found in infected 
intraamniotic fluid.17 
Controlled delivery of drugs can sustain blood level of a drug over a longer period of 
time, limit side effects, and lead the drug through the body without degradation, increase drug 
solubility, and decrease dose frequency.  It is well known that the functional surface groups on 
dendrimers can affect their physicochemical properties, making them hydrophilic. Conjugation 
of poorly water-soluble drugs to PAMAM dendrimers increases the bioavailability as well as 
drug solubility and decreases the dose frequency.18,40,41 Drug molecules can either be 
encapsulated and complexed, or covalently attached to the dendrimers through their functional 
groups.19,20 The most common covalent linkage of the drugs to the surface functional groups of 
dendrimers can be achieved through the ester or amide bond which can be cleaved hydrolytically 
or enzymatically.21 In the recent past disulfide bonds have also been demonstrated to be cleaved 
in presence of intracellular glutathione (GSH).25 Ligand can be attached to the dendrimer to 
increase the accumulation of drug at the targeted site.20 Neutral PAMAM dendrimers with no 
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targeting ligands have been shown to have an intrinsic ability to localize in cells associated with 
neuroinflammation  in a rabbit model of cerebral palsy.42 The key issues in the design of 
dendrimer-drug conjugates include improving drug payload; overcoming cytotoxicity especially 
in the case of cationic dendrimers; understanding the mechanism and dynamics of intracellular 
transport; and engineering the drug release at the appropriate tissue. The cellular uptake of 
dendrimer is also affected by their size, construct, surface functional groups and their charge.26,43 
Premature or lack of drug release from the dendrimer-drug conjugate before the appropriate time 
can decrease the in vivo effectiveness. 
Total joint replacement (TJR) has been very successful in restoring function and mobility 
to millions of patients worldwide since its advent more than thirty years ago. With improvements 
in prophylaxis against infection, the fatigue strength of the components, and skeletal fixation, 
wear debris- induced periprosthetic membrane inflammation has become the primary limitation 
to TJR longevity.44  There is currently no cure for aseptic loosening (AL) patients with osteolysis 
except revision surgery, primarily due to a lack of safe or effective drug candidate(s).45 A recent 
approach to limiting osteolysis has focused on reducing periprosthetic inflammation and 
enhancing periprosthetic bone quality.45-47 Erythromycin (EM) has been used for infectious 
disease for over 50 years.48 For the last decade, EM has attracted a great deal of attention 
because of its novel anti-inflammatory effects far beyond antibiotics.49,50 EM demonstrates a 
unique “phagocyte targeted delivery” property, favorable concentrating in 
monocyte/macrophages.51-54 There are accumulating evidence,55 that EM exerts its anti-
inflammatory effects through targeting to NF-κB signaling.56-58 Data from previous studies 
showed that EM inhibits wear debris-induced inflammation and osteolysis (both in vitro and in 
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vivo),55,59-62 suggesting that EM represents an appropriate drug candidate to prevent or treat 
periprosthetic membrane inflammation. However, delivering adequate levels of EM to the site of 
periprosthetic inflammation, without undesirable systemic side effects, presents a considerable 
challenge. The goal of this work is to develop and validate intravenously dendrimer-EM delivery 
nanodevices that can target the periprosthetic tissue and reduce local inflammation in a sustained 
manner.  
In this Chapter the synthesis and characterization of hydroxyl terminated generation four 
PAMAM dendrimer-Erythromycin conjugate (dendrimer-EM) and its in vitro activity and 
cytotoxicity is described. First, PAMAM G4-OH was partially functionalized with amine groups 
using amino-valeric acid as linker and then conjugated to EM-2′-glutarate via EM-glutarate-N-
succinimidyl ester intermediate.  The cell toxicity was determined by measuring the release of 
lactate dehydrogenase (LDH) from dead or dying cells into the culture medium using a 
Cytotoxity Detection Kit. A zone of inhibition study was performed using the modified Kirby-
Bauer Method to determine the levels of Staphylococcus aureus (S. aureus) activity inhibited by 
dendrimer-EM conjugate release in the sample eluents. The effect of dendrimer-EM conjugate 
on LPS-induced nitrite production in RAW 264.7 cells was demonstrated. The cell studies were 
done at the Biomedical Engineering by our collaborator, Dr. Ren’s lab. 
2.3 Materials and Methods 
2.3.1 Materials 
Generation four hydroxyl terminated PAMAM dendrimer (G4-OH) with ethylendiamine 
core and 64 surface groups (MW 14,279) in methanol solution was purchased from Dendritech 
Inc. (Midland, MI, USA). N-(3-dimethylaminopropyl)-N-ethylcarbodiimide (EDC), 4-
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(dimethylamino) pyridine (DMAP), glutaric anhydride, 5-(tert-butoxycarbonyl-amino)valeric 
acid, N,N-dimethylacetamide (DMA), diphenyl chlorophosphate and lipopolysaccharide (LPS, 
Escherichia coli O55:B5) were purchased from Sigma-Aldrich Chemical Company (St. Louis, 
USA). Triethylamine (TEA) and N-hydroxysuccinimide (NHS) were purchased from Thermo 
Scientific. Trifluoroacetic acid (TFA), dimethylformamide (DMF), and dimethyl sulfoxide 
(DMSO) were purchased from EMD. All anhydrous solvents DMSO, DMF, acetonitrile (ACN), 
and dichloromethane (DCM) were purchased from Acros Organics, USA. Fluorescein 
isothiocyanate (FITC) was obtained from Alfa Aesar, MA, USA. All other solvents and 
chemicals used were purchased from Fisher Scientific. Regenerated cellulose (RC) dialysis 
membrane with molecular weight cut-off of 1000 Da was obtained from Spectrum Laboratories. 
DMEM medium was purchased from Gibco-BRL Life Technologies, USA. FBS (fetal bovine 
serum) was purchased from HyClone Laboratories (Utah, USA). 
All reactions were carried out under nitrogen conditions. The anhydrous solvents and 
other reagents that are commercially available were directly used without further purification. 
Thin layer chromatography (TLC) was performed on silica gel GF254 plates (Watmann) and the 
spots were visualized with UV light and 2% H2SO4 in EtOH.  
2.3.2 Characterization 
NMR spectra were recorded on a Varian INOVA 400 spectrometer using commercially 
available deuterated solvents. Proton chemical shifts are reported in ppm (δ) and 
tetramethylsilane (TMS) used for internal standard. Coupling constants (J) are reported in hertz 
(Hz). ESI mass spectra were recorded on Waters Micromass ZQ spectrometer. Matrix-assisted 
laser desorption ionization-time of flight (MALDI-TOF) mass spectra were recorded on a Bruker 
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Ultraflex system equipped with a pulsed nitrogen laser (337 nm), operating in positive ion 
reflector mode, using 19 kV acceleration voltage and a matrix of 2,5-dihydroxybenzoic acid. 
Cytochrome C (MW 12,361 g/mol), and Apomyoglobin (MW 16,952 g/mol) were used as 
external standards. A dendrimer solution was prepared by dissolving 2 mg of dendrimer in 1 mL 
of DMSO. The matrix solution was prepared by dissolving 20 mg of matrix in 1 mL of the 1:1 
mixture of deionized water and acetonitrile (0.1% TFA). Analytical samples were prepared by 
mixing 10 µL of dendrimer solution with 100 µL of matrix solution, followed by deposition of 1 
µL of sample mixture onto a 384-well aluminum plate. This mixture was allowed to air dry at 
room temperature. 
2.3.3 HPLC Characterization 
High performance liquid chromatography (HPLC) characterization was carried out using 
Waters HPLC instrument equipped with dual pumps, an auto-sampler and dual UV detector 
interfaced to Breeze software. The HPLC chromatogram was monitored at 210 and 238 nm 
simultaneously using the dual UV absorbance detector. H2O:ACN (0.14 % TFA) was used as 
mobile phase. Both phases were freshly prepared, filtered, and degassed prior to use. 
Symmetry300 C18 reverse-phase column (5 µm particle size, 25 cm × 4.6 mm length × I.D.) 
equipped with a Supelguard Cartridges (5 µm particle size, 2.0 cm ×3.9 mm length × I.D.) was 
used for characterization of the conjugates. HPLC analysis was done using 90:10 to 30:70 
(H2O:ACN) gradient flow in 30 minutes with flow rate of 1 mL/min.  
2.3.4 Release Study Protocol 
The release studies were performed in 0.1M PBS buffer solution (pH = 7.4). The 
conjugate was added into 3 mL preheated buffer solutions in triplicates. All the release solutions 
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containing 2.5 mg/mL dendrimer drug conjugate were stirred continuously and maintained at 
37ºC. At appropriate time intervals samples were withdrawn and immediately analyzed by HPLC 
to determine the EM concentrations. 
2.3.5 Dynamic Light Scattering and ζ-Potential  
The particle size and ζ-potential of G4-OH and dendrimer conjugates were determined by 
dynamic light scattering (DLS) using a Malvern Instruments Zetasizer Nano ZEN3600 
instrument (Westborough, MA). The samples were dissolved in DI water (18.2 Ω) and filtered 
using AccuSpin Micro 17/17R ultracentrifuge (Fisher Scientific). DLS measurements were 
performed at a 173° scattering angle at 25°C.  
2.3.6 RAW 264.7 Cell Culture Stimulation, and Dendrimer Treatment 
Murine RAW 264.7 macrophage cell line was obtained from the American Type Culture 
Collection (ATCC, Rockville, MD). RAW 264.7 cells were maintained in Dulbecco’s modified 
Eagle’s medium (DMEM) (Gibco BRL, MD) containing 10% fetal bovine serum (FBS) and 
antibiotics (100 units/mL of penicillin-G and 100 µg/mL of streptomycin) at 37°C in a 
humidified incubator with 5% CO2.  RAW 264.7 cells were plated at a density of 1 × 105 
cells/well, in 96-well plates in the presence of LPS (1 µg/mL) with or without dendrimer-EM 
conjugate at different concentrations for 48 hours. 
2.3.7 Cell Toxicity Assay  
Cell toxicity was determined by measuring the release of lactate dehydrogenase (LDH) 
from dead or dying cells into the culture medium using a Cytotoxity Detection Kit (Roche 
Diagnostics BmbH) following the manufacturer’s instruction. 48 hours after treatment of 
dendrimer-EM conjugates at different concentrations, the conditioned media were collected and 
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used for the measurement of LDH activity. Briefly, 100 µL of culture medium was added into a 
plate of 96 wells, mixed with 100 µL working solution and incubated at room temperature for 30 
minutes in the dark. Then, the plate was read under the UVmax colorimeter (Molecular Devices) 
at OD 490 nm. Blank culture medium was used as a blank control and the total cell lysate was 
used as a positive control as well. LDH activity was expressed as absorbance (OD) per mg 
protein.  
2.3.8 Detection of Nitrite Production  
RAW 264.7 cells (passage 10) (5 × 105 cells per well) were cultured in triplicate in 24-
well plates and stimulated with 1 µg/mL LPS (positive control), and 1 µg/mL LPS [+EM, 
+dendrimer, or +D-EM] for 48 hours. The concentrations of free EM were 0.1, 1.0, 5.0, and 10.0 
µg. They corresponded to the concentration of EM in the dendrimer-EM conjugate. The 
production of nitric oxide (NO) was determined by assaying culture supernatant for nitrite 
(NO2−), a stable reaction product of NO. In brief, 100 µL of culture supernatant was mixed with 
an equal volume of Griess reagent (Cayman) (1% sulfanilamide and 0.1% N-[naphthyl] 
ethylenediamine dihydrochloride in 2.5% H3PO4) at room temperature for 10 min. Absorbance 
was measured at 540 nm in a microplate reader. Nitrite concentration was calculated from a 
NaNO2 standard curve.  
2.3.9 Antibacterial Assay  
Staphylococcus aureus (S. Aureus) strain was used for the present study. A zone of 
inhibition study was performed using the modified Kirby-Bauer Method to determine the levels 
of S. aureus activity inhibited by dendrimer-EM conjugate release in the sample eluents. Growth 
of the organism and diffusion of the EM commence simultaneously resulting in a circular zone 
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of inhibition in which the amount of dendrimer-EM conjugate exceeds inhibitory concentrations. 
The diameter of the inhibition zone reflects the function of the dendrimer-EM conjugate amount 
in the eluents. A disk paper soaked with the dendrimer-EM/PBS solution with known 
concentration was put into a bacterial agar plate, inoculated with the bacteria strain of S. aureus, 
for the zone of inhibition test.  This strain of S. aureus is the main bacteria causing bone 
infection. The bacteria plates were incubated for 24 hours, and then the diameter of the zone of 
growth inhibition around each disk to the nearest whole mm were measured. The results were 
expressed as the size of zone of inhibition. All the tests were performed in triplicate, and 
repeated two times.   
2.3.10 Preparation of Bifunctional PAMAM Dendrimer (G4-OH-Link-NH2, 2)  
The reaction scheme for the preparation of the conjugate 2 is outlined in Figure 5. The 5-
(Boc-amino)valeric acid (168.9 mg, 0.7774 mmole) was dissolved  in DMSO (10 mL). EDC 
(447 mg, 2.33 mmole) and DMAP (10.0 mg, 0.0818 mmole) each dissolved in DMSO (5 mL) 
were added under nitrogen atmosphere. The mixture was allowed to stir for 1 hour at room 
temperature and PAMAM G4-OH (370.0 mg, 0.0259 mmole) dissolved in DMSO (5 mL) was 
added to the reaction mixture. The reaction was stirred for 48 hrs at room temperature. The 
resulting solution was dialyzed extensively with DMSO (dialysis membrane of molecular weight 
cutoff = 1000 Da) for 24 h and with deionized water for 6 h. The obtained reaction mixture was 
then lyophilized yielding 328.0 mg (0.0194 mmole) of intermediate 1 (G4-OH-Link-Boc). The 
intermediate 1 contains Boc protected amino groups on the surface and it was characterized by 
proton NMR. 1H NMR (DMSO-d6, 400 MHz): δ (ppm) 8.04 (bs, CO-NH, Boc), 7.92 (bs, CO-
NH, G4-OH), 7.77 (bs, CO-NH, G4-OH), 4.69 (bs, OH, G4-OH), 3.96 (m, CH2OCO), 3.37-2.18 
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(986H, m, aliphatic protons of G4-OH and CH2 of linker), 2.01 (m, CH2, methylene protons of 
linker), 1.45 (m, 2 × CH2, methylene protons of linker), 1.34 (s, 3 × CH3, methyl groups of Boc).  
To obtain free amine groups, 6.0 mL of TFA:DCM (1:1) was added to 328.0 mg G4-OH 
conjugate containing Boc groups at 0°C. The reaction was carried out for 1 h at 0°C, and then the 
solvent was removed at reduced pressure. The mixture was re-dissolved in DMSO and dialyzed 
with DMSO for 24 h and deionized water for 6 h. The reaction mixture was then lyophilized 
yielding 220 mg of bifunctional dendrimer 2. The conjugate 2 was characterized by proton 
NMR. 1H NMR (DMSO-d6, 400 MHz): δ (ppm) 7.92 (bs, CO-NH, G4-OH), 7.77 (bs, CO-NH, 
G4-OH), 4.69 (bs, OH, G4-OH), 3.99 (t, CH2OCO), 3.40-2.47 (986 H, m, aliphatic protons of 
G4-OH and CH2 of linker), 2.31 (m, CH2, methylene protons of linker), 1.53 (m, 2 × CH2, 
methylene protons of linker).  
 
 
Figure 5. Synthesis of bifunctional PAMAM dendrimer (G4-OH-Link-NH2, 2). 
2.3.11 Synthesis of Erythromycin-2′-Glutarate (EM-2′-glutarate, 3)  
The reaction scheme is shown in Figure 6. Glutaric anhydride (31.09 mg, 0.272 mmole) 
and TEA (30 µL) were added to a solution of EM (100 mg, 0.136 mmole) in 80:20 (v/v) 
anhydrous DMF/DMA (10 mL). The reaction mixture was allowed to stir for 24 h under N2 and 
additional 15.54 mg (0.136 mmole) of glutaric anhydride and TEA (30 µL) was added. The 
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reaction mixture was continued to stir and was monitored with TLC. After 3 days of stirring, 
TLC (methanol/ethyl acetate/DCM = 5:2:2, Rf = 0.4) showed that reaction was complete.  The 
reaction mixture was evaporated under reduced pressure and pure EM-2′-glutarate was isolated 
by flash column chromatography on silica gel using methanol/ethyl acetate/hexanes (5:2:2) as 
mobile phase (100 mg, yield 86%).  
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Figure 6. Synthesis of EM-2’-glutarate 3 and Erythromycin-2′-glutarate-N-succinimidyl ester 4. 
EM-2′-glutarate was characterized by proton NMR, HPLC, and ESI MS. 1H NMR 
(DMSO-d6, 400 MHz): δ (ppm) 5.07 (dd, J1=11.6 Hz, J2=2.4 Hz, 1H), 4.72 (dd, J1=4.8 Hz, 
J2=0.9 Hz, 1H), 4.60 (d, J=7.6, 1H), 4.52-4.49 (m, 2H), 4.01-3.96 (m, 2H), 3.88 (d, J=9.6 Hz, 
1H), 3.69 (s, 1H), 3.67 (dd, 1H), 3.44-3.36 (m, 2H), 3.22 (s, 3H), 2.89 (d, J=8.8 Hz, 1H), 2.84 (d, 
J=7.6 Hz, 1H), 2.61 (dd, J1=11.2 Hz, J2=3.2 Hz, 1H), 2.287-2.13 (m, 8H), 2.11 (s, 6 H), 1.86 (t, 
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J=6.8 Hz, 1H), 1.80-1.74 (m, 1H), 1.71-1.63 (m, 4H), 1.59-1.46 (m, 2H), 1.39-1.31 (m, 1H), 1.23 
(s, 3H), 1.15-0.97 (m, 21 H), 0.81 (d, J=7.2 Hz, 3H), 0.72 (t, J=7.2 Hz, 3H). ESI MS (m/z): calcd 
for C42H72NO16 [M-H]+ 846.4, found 846.8.  
2.3.12 Synthesis of Erythromycin-2′-Glutarate-N-Succinimidyl Ester, 4 
The synthetic scheme is shown in Figure 6. EM-2′-glutarate (70.00 mg, 0.0825 mmole) 
was dissolved in 70:30 (v/v) anhydrous ACN:DCM (5 mL) and TEA (50 µL) and N-
hydroxysuccinimido-phosphate (SDPP) (39.00 mg, 0.1238 mmole) were added to the solution at 
0ºC. SDPP was synthesized following the literature procedure.63 After 6 hours of stirring the 
TLC (MeOH:EtOAc:DCM = 1:3:2, Rf = 0.48) showed that reaction was complete.. The reaction 
mixture was concentrated under vacuum and the pure product was isolated by flash column 
chromatography on silica gel using methanol/ethyl acetate/hexanes (1:5:1) as a mobile phase (67 
mg, yield 85%). The ester (4) was characterized by proton NMR. 1H NMR (CDCl3, 400 MHz): δ 
(ppm) 5.00 (dd, J1=11.2 Hz, J2=1.6 Hz, 1H), 4.84 (d, J=4.0 Hz, 1H), 4.82-4.76 (m, 1H), 4.56 (d, 
J=7.2 Hz, 1H), 3.95-3.92 (m, 1H), 3.88 (d, J=9.2 Hz, 1H), 3.76 (s, 1H), 3.54-3.50 (m, 1H), 3.46 
(d, J=7.2 Hz, 1H), 3.29 (s, 3H), 3.04 (d, J=7.2 Hz, 1H), 3.00 (d, J=9.6 Hz, 1H), 2.90-2.84 (m, 
2H), 2.83-2.78 (m, 3H), 2.75-2.67 (m, 1H), 2.63 (bs, 4H), 2.57-2.49 (m,1H), 2.41-2.38 (m, 1H), 
2.32 (s, 6H), 2.54-1.99 (m, 2H), 1.93-1.86 (m, 2H), 1.82-1.69 (m, 2H), 1.61-1.50 (m, 3H), 1.42 
(s, 3H), 1.25-1.09 (m, 21 H), 0.86 (d, J=7.6 Hz, 3H), 0.80 (t, J=7.6 Hz, 3H).  
2.3.13 Preparation of G4-PAMAM Dendrimer-EM Conjugate (Dendrimer - EM, 5)  
The reaction scheme for the preparation of dendrimer-EM conjugate (5) is outlined in 
Figure 7. To a stirring solution of bifunctional dendrimer 2 (64 mg, 0.0041 mmole) in anhydrous 
DMSO (6.5 mL), TEA (10 µL) was added under nitrogen condition. To this solution EM-2′-
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glutarate-N-succinimidyl ester (67 mg, 0.0708 mmole) dissolved in anhydrous DMSO (5 mL) 
was added and the reaction mixture was allowed to stir for overnight at room temperature. After 
completion of the reaction, the reaction mixture was subjected to dialysis in DMSO (membrane 
MW cut off = 1000 Da) for 24 hours and in deionized water for 6 hours. The obtained reaction 
mixture was lyophilized to get final dendrimer-EM conjugate 5. The conjugate 5 was 
characterized by proton NMR. 1H NMR (DMSO-d6, 400 MHz): δ (ppm) 8.05 (bs, CO-NH, 
linker), 7.94 (bs, CO-NH, G4-OH), 7.79 (bs, CO-NH, G4-OH), 5.07 (d, J=12.4Hz, 1H, Ery), 4.9-
4.5 (m, OH, G4-OH; 3H, Ery), 4.11 (m, 2H, Ery), 3.97 (m, CH2OCO, G4-OH), 3.88 (d, 
J=12.4Hz, 1H, Ery), 3.70 (bs, 1H, Ery), 3.37-2.16 (m, 986 H aliphatic protons, G4-OH; CH2, 
linker; 24H, Ery), 2.06-1.28 (m, 4H, linker; 9H, Ery), 1.22 (s, 3H, Ery-CH3), 1.14-0.96 (m, 21 H, 
Ery-CH3),  0.80 (m, 3H, Ery-CH3),, 0.72 (m, 3H, Ery-CH3).  
 
Figure 7. Synthesis of PAMAM G4-OH-Erythromycin (Dendrimer-EM, 5).   
2.4 Results  
2.4.1 Synthesis and Characterization of Bifunctional PAMAM Dendrimer, 2  
Due to better reactivity of amine groups compared to hydroxyl groups, a bifunctional 
dendrimer was prepared. The reaction scheme is shown in Figure 5. 5-Boc-amino-valeric acid 
was used as a linker to provide protected NH2 groups. Generation four hydroxy-terminated 
PAMAM dendrimer (G4-OH) was reacted with activated 5-Boc-amino-valeric acid in presence 
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of EDC and catalytic amount of DMAP to yield intermediate 1. The intermediate was confirmed 
by  proton NMR  chemical shift and integration of Boc protected groups (s, 1.34 ppm, 9H), as 
well as chemical shifts of methylenes that belong to the linker (m, 1.45 ppm, 4H) and dendrimer 
ester methylenes  (m, 3.96 ppm, CH2OCO) that appear after conjugation (Figure 8). The 
integration of characteristic peaks for Boc groups and amide peaks of dendrimer obtained from 
NMR spectrum suggested that 13 molecules of Boc-linker were conjugated to the dendrimer.  
 
Figure 8. Proton NMR of intermediate 1 (G4-OH-Link-Boc). 
The deprotection of Boc-protected amino groups in mild condition, TFA:DCM (1:1), 
gave bifunctional dendrimer 2 which consists of 54 hydroxyl and 10 amine groups. The slightly 
lower number of NH2 groups (10 instead 13) are most probably due to hydrolysis of ester bond. 
The number of amine groups was determined based on proton NMR from integration of 
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characteristic peaks for methylene protons that belong to the linker (m, 1.45 ppm, 4H) and amide 
protons of dendrimer (Figure 9).  
 
Figure 9. Proton NMR of bifunctional PAMAM dendrimer (G4-OH-Link-NH2, 2). 
2.4.2 Synthesis of G4-PAMAM Dendrimer-EM Conjugate, 5 
The amino groups of bifunctional dendrimer were conjugated to EM-2′-glutarate through 
stable amide bond (Figure 7). Prior to conjugation of dendrimer with EM-2′-glutarate, EM-
glutarate-N-succinimidyl ester was prepared.63 EM consists of a 14-membered lactone ring with 
ten asymmetric centers, and glycosylated in two positions by desosamine and cladinose sugars.64 
Cladinose is linked to the 4-position while desosamine to the 6-position of the lactone ring. EM 
also contains four hydroxyl groups that differ in their reactivities. The order of reactivity was 
established by acetylation. The most reactive hydroxyl group is at 2′-position where acetylation 
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occurs first due to vicinity of tertiary amine that acts as an autocatalyst.65,66 When limiting 
amount of acetic anhydride is used, the 2′-monoacetate would be the only product, and it can be 
obtained without any catalyst. The tertiary amine group also increases the rate of 2′-monoacetate 
hydrolysis, which can be achieved by quenching the reaction with methanol. The second most 
reactive hydroxyl group is at 4′′-position, while the third one is at 11-position. The reaction of 
EM with glutaric anhydride in the presence of triethylamine occurred at 2′-position which gave 
EM-2′-glutarate 3 and was characterized by HPLC, proton NMR, and mass spectroscopy. The 
molecular weight of 3 from mass spectrum [M-H]+ was found to be 846.8 which is in agreement 
with calculated one, 846.4 (Figure 10).  
 
Figure 10. ESI MS of Erythromycin-2′-glutarate (EM-2’-glutarate) 3, (m/z): calc. for 
C42H72NO16 [M-H]+ 846.49, found 846.79.  
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Analysis of proton NMR spectrum showed that th chemical shifts of H-1′ (d, 4.60 ppm, J=7.6 
Hz), H-2′ and H-3′ (m, 4.52-4.49 ppm) of desosamine as well as overlapping signals for 
methylene protons that belong to the glutarate moiety and EM (m, 1.71-1.63 ppm and m, 2.28-
2.13 ppm) confirmed the formation of EM-2′-glutarate (Figure 11).  
 
Figure 11. Proton NMR of Erythromycin-2′-glutarate (EM-2′-glutarate) 3. 
The HPLC chromatograms showed that the retention times for EM and EM-2′-glutarate were 
22.08 and 23.66 min respectively (Figure 12). EM-2′-glutarate was then reacted with SDPP in 
the presence of triethylamine to obtain activated ester of Erythromycin 4. The ester was 
characterized by proton NMR showing characteristic peak for methylene protons of succinimide 
ester (s, 2.63 ppm, 4H) (Figure 13). We achieved better yield when SDPP was used compared to 
N-hydroxysuccinimide. The activated ester of EM was coupled with bifunctional dendrimer to 
yield dendrimer-EM conjugate.  
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Figure 12. HPLC chromatograms of Erythromycin, and Erythromycin-2′-glutarate (3) at 210 
nm. 
 
Figure 13. Proton NMR of Erythromycin-2′-glutarate-N-succinimidyl ester 4. 
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Dendrimer-EM conjugate was characterized by HPLC and compared to bifuctional 
dendrimer and G4-OH as shown in Figure 14. The analysis of HPLC spectra showed that the 
retention time of G4-OG (7.96 min) was very close to bifunctional dendrimer (8.13 min), since 
there is no significant difference in chemical structure. However, the dendrimer-EM and G4-OH-
Link-Boc intermediate gave very distinct broad peaks at 11.69 and 13.13 min, respectively. The 
broad peaks are due to larger size and non-polar character of conjugates compared to G4-OH and 
bifunctional dendrimer.  
 
Figure 14. HPLC chromatograms of G4-OH, bifunctional dendrimer G4-OH-Link-NH2 (2), 
Dendrimer-EM conjugate (5), and G4-OH-Link-Boc (1) at 210 nm. 
 
The proton NMR of dendrimer-EM conjugate is shown in Figure 15. Comparison of the 
integration of amide peaks of dendrimer and methyl groups of EM revealed that four molecules 
of EM were attached to the surface of the dendrimer.  
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Figure 15. Proton NMR spectrum of dendrimer-EM (5) in DMSO-d6. 
 
MALDI-TOF MS spectra of dendrimer-EM were evaluated and compared with G4-OH 
which is shown in Figure 16. The obtained molecular weight of dendrimer-EM conjugate 
(18,203.6), also suggests that a payload of approximately four molecules of EM was achieved. 
This represents a drug payload in the conjugate of ~16% by weight, which is relatively high for a 
polymer-drug conjugate. The conjugate was soluble in PBS buffer pH 7.4, in contrast to the free 
drug. 
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Figure 16. MALDI-TOF MS spectra of (a) dendrimer-EM (5), and (b) G4-OH dendrimer. 
 
2.4.3 Particle Size and ζ-Potential 
Zeta potential and size of the nanoparticle or drug molecule plays a major role in 
targeting and delivery to the specific site. It is also influences the binding properties of the drug 
and dendrimer/nanoparticle to the receptor. We have investigated particle size and zeta potential 
of G4-OH, bifunctional dendrimer (2) and dendrimer-EM conjugate (5) which are shown in 
Table 2. We did not find much difference in size between G4-OH, G4-OH-Link-Boc and 
bifunctional dendrimer (2); this may be due to minimal difference in molecular weight of these 
molecules. The dendrimer-EM conjugate has slight larger size (4.98 nm) compared to others. 
The G4-OH has less cytotoxicity due to its neutral surface charge. It has slightly positive zeta 
potential (4.54 mV) which is due to the presence of tertiary amines in its core even though it 
34 
 
suppose to have neutral value. We did not find any difference between G4-OH and G4-OH-Link-
Boc, but there is a difference between G4-OH and G4-OH-Link-NH2 (2). This is due to an 
increase in number of primary amine (12-13 groups) on the surface of the dendrimer after 
deprotection of Boc groups (6.29 mV).  The zeta potential of dendrimer-EM conjugate is 8.08 
mV. The tertiary nitrogen groups of erythromycin are responsible for slightly higher value of 
dendrimer-EM compared to G4-OH and bifunctional dendrimer.  
 
Table 2. Particle size and ζ-potential of dendrimer conjugates 
Compound                           Diameter (nm)           ζ-potential (mV) 
G4-OH                                       4.28±0.24                   +4.54±0.10 
G4-OH-Link-Boc                      4.53±0.30                   +4.92±1.20 
G4-OH-Link-NH2                      4.22±0.28                   +6.29±2.50 
Dendrimer-EM                          4.98±0.50                   +8.08±0.90 
 
2.4.4 Release Studies  
The drug release rate of the conjugate was carried out in PBS buffer at pH 7.4 and 
analyzed by HPLC. The ester linkage used for conjugation of EM was susceptible to hydrolysis 
and about 90% of the EM was released within 10 hours (Figure 17). EM release from the 
conjugate was completed within 20 hours. There are two ester links in the dendrimer-EM 
conjugate, and the release study clearly showed that ester bond on the 2′-position releases 
preferentially. This is consistent with the previous studies where EM-2′-monoacetate easily 
hydrolyzes when the reaction quenched with methanol due to vicinity of tertiary amine group. 
This tertiary amine group acts as an autocatalyst for the hydrolysis of ester bond.65,66  
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Figure 17. Drug release profile of dendrimer-EM conjugate (5) in PBS buffer pH 7.4. 
 
To confirm that the EM release was due to hydrolysis of the ester linkage another control 
experiment was carried out. The conjugate was dissolved in anhydrous DMSO and the stability 
was analyzed for 24 hours. The conjugate was completely stable in anhydrous condition and did 
not release any EM.  The drug release from the conjugate followed pseudo-first order reaction 
kinetics (k’ = 0.36 h-1, t1/2 = 1.9 hrs) as determined by plotting natural logarithm of ester linked 
EM against time (Figure 17). The rate constant was determined from the linear regression of this 
graph where the slope of the line is the reaction rate constant. This release profile is very 
appropriate for the present application and it is anticipated that the dendrimer will transport the 
drug inside cells and release it over a period of several hours. 
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2.4.5 The Cytotoxicity of Dendrimer-EM Conjugates on RAW 264.7 Macrophages 
In order to assess the efficacy, it was important to show that the conjugate was non 
cytotoxic. The concentrations of EM in the X-axis are on drug basis (Figure 18). The free 
dendrimer concentration was based on the amount of dendrimer present in the dendrimer-drug 
conjugate, at the indicated EM concentration. For example, at the highest concentration of EM 
(10 µg/mL), is equivalent to ~60 µg/mL of dendrimer-EM conjugate. Therefore, 50 µg/mL of the 
free dendrimer was used as control.  
 
Figure 18. Effect of dendrimer-EM conjugate (5) on the release of LDH in LPS-stimulated 
RAW 264.7 cells. Three independent experiments were performed, and data are mean ± SD of 
six samples per group.  
 
As shown in Figure 18, free dendrimer, EM and dendrimer-EM conjugate did not show 
appreciable cytotoxicity in LPS activated RAW 264.7 cells at the concentrations up to 10 µg/mL 
37 
 
for a treatment period of 48 hours, based on the LDH assay. Since these are the same activated 
cells on which the efficacy is tested, the non-cytotoxic behavior of the compounds suggests that 
the efficacy reported is primarily due to the anti-inflammatory activity. 
2.4.6 Dendrimer-EM Conjugate Inhibited NO Production  
RAW 264.7 cells were cultured with LPS (1 µg/mL) in the presence of dendrimer-EM for 
48 hours, a concentration-dependent inhibition of NO2- generation was observed (Figure 19). 
These macrophages are the in vivo targets in the orthopedic applications envisages for these 
conjugates. The stimulation by LPS causes the macrophages to release the inflammatory 
markers, suppression of which would be a measure of efficacy. As shown in Figure 19, 
dendrimer-EM significantly inhibited  NO2-  release, as  compared  with   untreated   cells,   and  
EM-treated   cells   at   the concentration of 1-10 µg/mL. Interestingly, we also noticed that 
dendrimer-EM demonstrated much stronger NO2- production inhibition than free EM at the 
dosage range of 5-10 µg/mL. The improved in vitro activity of the dendrimer-EM conjugate 
where the drug and the dendrimer are ester-linked is significant, since polymer-drug conjugates 
for cancer applications typically show lower activity in vitro, compared to free drug.18,31 This 
suggests that enabling an effective intracellular drug release profile (as shown in Figure 17) is 
crucial for improved efficacy. The improved anti-inflammatory activity of the conjugate is 
qualitatively comparable to the improvements in the activity of dendrimer-N-acetyl cysteine 
conjugates with glutathione sensitive linkers.25 
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Figure 19. Effect of dendrimer-EM conjugate (5) on LPS-induced nitric oxide production in 
RAW 264.7 cells.  Five independent experiments were performed, and data are mean ± SD of six 
samples per group. * p< 0.05 EM vs. dendrimer-EM, ** p< 0.05 EM, and dendrimer-EM vs. 
LPS group.  
 
2.4.7 Dendrimer-EM Conjugate Still Preserves Its Antibacterial Activity 
The antibacterial activity of the dendrimer-EM conjugate at different concentrations is 
shown in Figure 20. Based on a zone of inhibition evaluation, the dendrimer-EM conjugate 
showed similar activity, as compared to free EM with the same concentration. Furthermore, free 
dendrimer did not show any effect of bacterial inhibition at the concentration up to 0.2 mg/mL. 
This suggests that, either conjugation to dendrimers did not affect the antibacterial activity of 
EM, or free EM was released from the conjugate within the 24 hour period. It is most likely the 
latter, since the drug releases from the conjugate appreciably over this period (as shown in the 
release data). Of course, it is not clear if the EM is released outside the bacteria and is taken up 
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as free EM, or if the conjugate is internalized and the drug is released inside the cell. The results 
suggest that the conjugation to dendrimer did not negatively affect the antibacterial activity, 
while producing a superior anti-inflammatory activity. 
  
 
Figure 20. Zone inhibition induced by EM at different concentration. (A) Disk papers soaked 
with the PBS solution containing different concentration of dendrimer, EM and dendrimer-EM 
conjugate were put into a bacterial agar plate (inoculated with the bacteria strain of S. aureus for 
the zone of inhibition test. The bacteria plates were incubated for 24 hours, and then the diameter 
of the zone of growth inhibition around each disk to the nearest whole mm were measured. (B) 
Quantitative analysis of the size of zone of inhibition (mm) among different compounds. All the 
tests were performed in triplicate, and repeated two times.                               
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2.5 Discussion 
In recent years, dendrimer-based nanocarriers have been extensively used for drug and 
gene delivery. The drugs are attached to dendrimer surface functional groups either directly or 
via spacers, and very often with targeting moiety (ligand to receptor). The most common bonds 
are ester and amide, which can be hydrolyzed inside the cell by endosomal or lysosomal 
enzymes. The drug release due to hydrolysis is governed by the pH, and ester bonds are more 
labile towards the hydrolysis compared to amide bonds.22 Studies have shown that ester-linked 
conjugates can be hydrolyzed by esterase enzymes in human plasma, while amide bonds are 
quite stable.23,24  A key challenge for dendrimer-drug conjugates is to engineer systems where 
the drug is released over a time scale appropriate for the application.  
In this study, a neutral PAMAM dendrimer-EM conjugate was prepared and evaluated 
for its anti-inflammatory and antibacterial activity. The hydroxy-terminated PAMAM 
dendrimers are more biocompatible and significantly less cytotoxic than the amine-terminated 
counterparts.67 PAMAM G4-OH was reacted to a protected amine linker followed by 
deprotection to obtain a bifunctional dendrimer that contains 10-15% amine groups. EM was 
modified to EM-2’-glutarate and conjugated to the bifunctional dendrimer through an amide 
bond. A combination of HPLC, proton NMR and MALDI-TOF analyses showed that the 
conjugates were ‘pure’ with a drug payload of ~16% by weight, which is relatively high for 
polymer conjugates, yet was very soluble in PBS buffer. The conjugate released the drug 
effectively, with more than 90% of free drug over a period of 10 h. The efficient release of drug 
from 2’-position of EM preferentially is due to tertiary amine group present in the vicinity of 2′-
position in EM. The conjugate was non cytotoxic to RAW 264.7 macrophages (the target cells 
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for anti-inflammatory activity), and showed improved efficacy over free drug. In LPS activated 
macrophages, the conjugate was more effective in reducing nitrite production (a measure of anti-
inflammatory activity) compared to free drug. The antibacterial activity of the conjugate was 
comparable to free drug. 
Our study indicated that the dendrimer-EM conjugates have a high drug payload (16%), 
and improve the solubility of the drug, and could lead to improved activity. These are especially 
important in delivering sufficient amount of EM to the site of periprosthetic inflammation and 
reducing local inflammation in a sustained manner.  
2.6 Future Work 
2.6.1 In Vivo Efficacy of Dendrimer-EM Conjugate 
Since dendrimer-EM showed an improved efficacy in vitro compared to free EM, an in 
vivo study can be demonstrated using BALB/C mouse osteolysis model. Dr. Ren and his group 
used this model to evaluate in vivo efficacy of free EM.59 It is created by introducing the 
ultrahigh molecular-weight polyethylene (UHMWPE) into established air pouches on BALB/c 
mice where UHMWPE debris induces tissue inflammation. A preliminary study was done by Dr. 
Ren in collaboration with our group where these mice were treated with dendrimer-FITC 
conjugates (Figure 21). As it can be seen from the images dendrimers showed to have an affinity 
for preferential accumulation in areas associated with periprosthetic inflammation. Based on 
these results we can expect that dendrimer-EM nanodevices can lead to improved in vivo 
efficacy that is the delivering of sufficient amount of EM using dendrimer as a vehicle to the site 
of periprosthetic inflammation and the local inflammation could be reduced in a sustained 
manner.  
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Figure 21. BALB/C mice, osteolysis model, treated with: (A) PAMAM dendrimer-FITC (green) 
- intraperitonial administration, (B) Saline solution with free FITC - intravenous administration, 
and(C) PAMAM dendrimer-FITC (green) - intravenous administration. 
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CHAPTER 3 “PAMAM DENDRIMER-BASED DIAGNOSTIC NANODEVICES FOR 
IMPROVED DETECTION OF TNF-α CYTOKINE”  
3.1 Abstract 
A novel dendrimer-based sandwich type enzyme-linked immunosorbent assay (ELISA) 
kit was developed for the detection of recombinant human tumor necrosis factor-alpha (TNF-α). 
Hydroxyl terminated generation four poly(amidoamine) dendrimer (PAMAM-OH) was used for 
the development of a solid phase bio-sensing platform. The surface of the ELISA plate was 
modified with polyethylene-glycol (PEG) by reacting PEG-maleimide and PEG-hydroxy to get 
maleimide reactive surface groups. A thiol functionalized PAMAM-OH was synthesized and 
immobilized on the PEG-functionalized assay plate and the remaining thiol groups of dendrimer 
were converted to hydrazide groups. A capture antibody was oxidized and covalently 
immobilized onto dendrimer-modified ELISA plate which gives antibody favorable orientation 
for the antigen binding sites toward the analyte. The dendrimer modified plate showed enhanced 
sensitivity and the detection limit for TNF-α was found to be 0.48 pg/mL, which is significantly 
better than the commercially available ELISA kit. The selectivity of the dendrimer-modified 
ELISA plate was examined by studying TNF-α in a mixture of cytokines which gave similar 
results. Dendrimer-modified ELISA plate provides a greater opportunity for the detection of a 
wide range of cytokines and biomarkers. 
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3.2 Introduction 
One of the greatest challenges faced by modern perinatal medicine is preterm birth (PTB) 
and perinatal morbidity. Intra-amniotic infection/inflammation (IAI) is one of the most important 
causes of preterm birth. The relationship between IAI and preterm labor has been well 
established.68 It accounts for 75% of perinatal mortality and 50% of perinatal morbidity.69,70 
Early detection of the infection is also challenged by the sub-clinical nature of the disease.71,72  
Fever, uterine tenderness and fetal tachycardia occur late in pregnancy and present in small 
portion (12.5%) of the women with microbiological evidence of infection.73,74 An elevated level 
of pro-inflammatory cytokines (TNF-α, IL-6, IL-1β, and MMP-8) are found in infected intra-
amniotic fluid, which are biomarkers for early detection.75,76 The development of sensitive and 
specific diagnostic device which will enable an early detection and treatment to prevent fetal 
damage would be of great interest. The importance of detection of these cytokines is also 
enhanced by their association with pulmonary and neurodegenerative diseases. There are plenty 
evidence to prove the presence of an elevated level of TNF-α in the patients suffering from 
Alzheimer's disease77, Parkinson’s disease78, Multiple Sclerosis79 and Chronic Obstructive 
Pulmonary disease (COPD)80. 
TNF-α is a pro-inflammatory cytokine that regulates the immune system inducing 
inflammation and apoptosis in many organs of the body. In the brain, overexpression of TNF-α 
in microglia cells causes neural death which is linked with neurological disorders. An increased 
level of TNF-α is also associated with pre-term birth and cerebral palsy.81 Therefore, determining 
the level of TNF-α in amniotic fluid is essential for an understanding of the mechanism of pre-
term birth and its prevention. Enzyme-linked immunosorbent assay (ELISA) is the most 
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common method used to determine the concentration of TNF-α. In literature, beside the ELISA, 
various methods have been reported for determination of TNF-α concentration. These methods 
include radioimmunoassays (RIA),82 bioassays,83 chemiluminescence84 and chemiluminescence 
imaging85, matrix-assisted laser desorption/ionization mass spectrometry (MALDI-MS)86, 
immuno-PCR87 and immuno-PCR assay88, fluorescence immunoassay89, and electrochemical 
immunosensor90. The detection limits for cytokines of currently used immunosensors are at a 
much higher level of concentration. Our goal is to develop a diagnostic device that will detect the 
presence of TNF-α at a lower level by improving its sensitivity and specificity. The solid-liquid 
interface results in sensitivity, and interaction at the analyte-ligand provides selectivity and 
stability.91 In developing an immunosensor, the immobilization of antibodies is a key step. The 
antibodies should be immobilized onto a substrate at high density with uniform distribution 
followed by retaining their specific antigen-binding activities, and finally maintaining 
accessibility to the antigens.16 The aim is to develop a biosensor which will maximize the 
biochemical activity and minimize nonspecific protein adsorption. In effort to improve the 
existing detecting devices, use of dendrimers could play a very important role. 
Unlike linear polymers, dendrimers do not form entangled chain but unique in shape with 
numerous chain ends which can be functionalized. They are stable, can be closely packed on the 
substrate surface, and have multiple branch ends available for further conjugation.92,93 
Dendrimers have all the specification to be used in next generation of biosensors.8,94 Dendrimers 
have been recently reported to significantly increase binding ability and homogeneity in DNA 
microarray analysis.11,95,96 Dendrimers are also utilized in electrochemical immunosensor,13,97 
biosensor-based encapsulated Platinum nanoparticles,9,98 regenerable affinity-sensing surfaces15 
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and surface plasmon resonance biosensor99. The application of dendrimer is extended to 
preparation of metal-dendrimer nanocomposites using PAMAM dendrimers with various 
terminal groups.100-101 Carboxyl terminated PAMAM dendrimers have shown to lower the 
nonspecific cellular protein adsorption and enhancing antibody binding properties.16 
Recently we have reported a highly sensitive dendrimer-based biosensing platform for 
IL-6 and IL-1β cytokines detection in which pegylated ELISA plate was modified using amine 
terminated PAMAM dendrimer.17 In continuing our effort, we have developed a solid phase 
biosensing platform using generation four hydroxyl terminated PAMAM dendrimer for TNF- α 
cytokine detection. The synthesis, characterization, fabrication and functional evaluation of this 
biosensing platform for TNF-α detection is described in this Chapter. The plate surface was co-
immobilized with hydroxyl polyethylene glycol (NH2-PEG-OH) and maleimide PEG (NH2-
PEG-Mal). Maleimide PEG was covalently linked to PAMAM dendrimers on the surface of the 
plate leading to controlled dendrimer grafting density which is also responsible for the increased 
grafting density of the antibody. The modified ELISA plate with long PEG arms and 
functionalized-dendrimer provides diffusional and conformational flexibility, which gives more 
favorable antibody-antigen interactions. The resulting dendrimer functionalized plate was 
employed as template to immobilize the anti-human TNF-α antibody and the performance was 
evaluated by the detection of TNF-α using TMB detection method. The dendrimer-based assay 
was compared to commercially available TNF-α kit. 
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3.3 Materials and Methods 
3.3.1 Materials 
Hydroxyl terminated generation four poly(amidoamine) dendrimer (G4-OH) was 
obtained from Dendritech Inc. N-(3-dimethylaminopropyl)-N-ethylcarbodiimide hydrochloride 
(EDC), 4-(dimethylamino)pyridine (DMAP), N-succinimidyl-3-(2-pyridyldithio)-propionate 
(SPDP), tris(2-carboxyethyl) phosphine (TCEP) and MALDI-TOF mass reference standards 
were purchased from Sigma-Aldrich. Trifluoroacetic acid (TFA) was obtained from EMD 
Chemicals. Hydoxyl terminated Polyethylene glycol (NH2-PEG-OH, 2.0 kDa) and 
maleimide terminated PEG (NH2-PEG-Mal, 3.4 kDa) were obtained from JenKem Technology, 
Beijing, China and Creative PEGworks, Winston Salem, USA respectively. DMSO-d6 was from 
Cambridge Isotope Laboratories. Anhydrous DMSO and dichloromethane (DCM) were from 
Acros Organics, USA. N-(ε-maleimidocarproic acid) hydrazide (EMCH) was from Pierce. All 
other solvents and chemicals used were from Fisher Scientific. Regenerated cellulose (RC) 
dialysis membrane (molecular weight cut-off 1000 Da) was obtained from Spectrum 
Laboratories. Recombinant human TNF-α, monoclonal TNF-α anti-human antibody, biotinylated 
anti-human TNF-α antibody, streptavidin-HRP (DY998), reagent diluent (DY995), substrate 
reagent (TMB, DY999), stop solution (DY994) and wash buffer (WA126) were obtained from 
R&D Systems. ELISA plates were purchased from Corning (high bind plate). 
3.3.2 NMR Spectra Analysis  
NMR spectra were recorded on a Varian INOVA 400 spectrometer using DMSO-d6. 
Proton chemical shifts are reported in ppm (δ) and tetramethylsilane (TMS) used for internal 
standard.  
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3.3.3 MALDI-TOF Mass 
Matrix-assisted laser desorption ionization-time of flight (MALDI-TOF) mass spectra 
were recorded on a Bruker Ultraflex system. Cytochrome C (MW 12,361 g/mol), and 
Apomyoglobin (MW 16,952 g/mol) were used as external standards. A dendrimer solution was 
prepared by dissolving 2 mg of dendrimer in 1 mL of DMSO. The matrix solution was prepared 
by dissolving 20 mg of trans-3-indoleacrylic acid matrix in 1 mL of the 1:1 mixture of deionized 
water and acetonitrile (0.1% TFA). Analytical samples were prepared by mixing 10 µL of 
dendrimer solution with 100 µL of matrix solution, followed by deposition of 1 µL of sample 
mixture onto a 384-well aluminum plate. This mixture was allowed to air dry at room 
temperature. All data processing was performed using Bruker Daltonics flexAnalysis software. 
3.3.4 HPLC 
High performance liquid chromatography (HPLC) characterization was carried out using 
Waters HPLC instrument. Two pumps, an auto-sampler and dual UV detector are interfaced to 
Breeze software. The HPLC chromatogram was monitored at 210 and 238 nm simultaneously 
using the dual UV absorbance detector. H2O:ACN (0.14% TFA) was used as mobile phase. Both 
phases were freshly prepared, filtered, and degassed prior to use. Symmetry300 C18 reverse-
phase column (5 µm particle size, 25 cm × 4.6 mm length × I.D.) equipped with a Supelguard 
Cartridges (5 µm particle size, 2.0 cm ×3.9 mm length × I.D.) was used for characterization of 
the conjugates. HPLC analysis was done using 90:10 to 30:70 (H2O:ACN) gradient flow in 30 
minutes with flow rate of 1 mL/min.  
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3.3.5 Synthesis of Bifunctional G4 PAMAM-OH-PDP Dendrimer  
The reaction scheme for the preparation of the bifunctional G4 PAMAM-OH-PDP is 
outlined in Figure 22. The 5-(Boc-amino)valeric acid (228.2 mg, 1.0504 mmole) was dissolved 
in DMSO (10 mL), then EDC (603.8 mg, 3.15 mmole) and DMAP (12.0 mg, 0.0982 mmole) 
were added under nitrogen atmosphere. The mixture was allowed to stir for 1 hour at room 
temperature and PAMAM G4-OH (500.0 mg, 0.0350 mmole) dissolved in DMSO (5 mL) was 
added to the reaction mixture. The reaction was stirred for 48 hours at room temperature. The 
resulting solution was dialyzed extensively with DMSO (dialysis membrane of molecular weight 
cutoff = 1000 Da) for 24 hours and with deionized water for 6 hours. The obtained reaction 
mixture was then lyophilized yielding 445.0 mg (0.0242 mmole) of G4-OH-Link-Boc 
intermediate. This intermediate contains Boc protected amino groups on the surface. 1H NMR 
(DMSO-d6, 400 MHz): δ (ppm) 8.04 (bs, CO-NH, Boc), 7.92 (bs, CO-NH, G4-OH), 7.77 (bs, 
CO-NH, G4-OH), 4.69 (bs, OH, G4-OH), 3.96 (m, CH2OCO), 3.37-2.18 (986H, m, aliphatic 
protons of G4-OH and CH2 of linker), 2.01 (m, CH2, methylene protons of linker), 1.45 (m, 2 × 
CH2, methylene protons of linker), 1.34 (s, 3 × CH3, methyl groups of Boc).  
 
Figure 22.  Synthesis of G4 PAMAM-OH-PDP dendrimer . 
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The deprotection of Boc protected amino groups was done by adding 6.0 mL of TFA:DCM (1:1) 
to 445.0 mg of G4-OH-Link-Boc in a round bottom flask at 0oC. The reaction was carried out for 
1 hour at 0 °C, and then the solvent was removed at reduced pressure. The mixture was re-
dissolved in DMSO and dialyzed with DMSO for 24 hours and deionized water for 6 hours. The 
reaction mixture was then lyophilized yielding 298 mg of bifunctional dendrimer. 1H NMR 
(DMSO-d6, 400 MHz): δ (ppm) 7.92 (bs, CO-NH, G4-OH), 7.77 (bs, CO-NH, G4-OH), 4.69 (bs, 
OH, G4-OH), 3.99 (t, CH2OCO), 3.40-2.47 (986 H, m, aliphatic protons of G4-OH and CH2 of 
linker), 2.31 (m, CH2, methylene protons of linker), 1.53 (m, 2 × CH2, methylene protons of 
linker). Then the bifunctional dendrimer (150.0 mg, 0.00937 mmole) was dissolved in 9 mL of 
PBS, pH=7.4. To this SPDP (87.0 mg, 0.2798 mmole) in 3.5 mL ethanol was added. The 
reaction mixture left to react for 2 hours at room temperature. The resulting solution was 
dialyzed extensively with water (dialysis membrane of molecular weight cutoff = 1000 Da) for 
24 hours. The obtained reaction mixture was then lyophilized yielding 90.0 mg (0.00529 mmole) 
of G4 PAMAM-OH-PDP dendrimer conjugate. The conjugate was characterized by proton 
NMR.  1H NMR (DMSO-d6, 400 MHz): δ (ppm) 8.43 (d, 1H, pyridyl H), 8.12 (bs, CO-NH, 
linker, G4-OH), 7.98 (bs, CO-NH, G4-OH), 7.81 and 7.73 (m, pyridyl Hs), 7.22 (t, 1H, pyridyl 
H), 4.75 (bs, OH, G4-OH), 3.98 (m, CH2OCO), 3.51-2.08 (m, 990H, aliphatic protons of G4-
OH, CH2 of linker, and CH2 of PDP.), 2.04 (m, CH2, methylene protons of linker), 1.48 (m, CH2, 
methylene protons of linker), 1.36 (m, CH2, methylene protons of linker). MALDI-TOF (pos) 
m/z 17141.1. 
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3.3.6 Synthesis of EMCH Functionalized G4 PAMAM-OH-PDP Dendrimer  
The reaction scheme of EMCH functionalized G4 PAMAM-OH-PDP synthesis is shown 
in Figure 23. The G4 PAMAM-OH-PDP dendrimer (2.4 mg, 140 nmole) was dissolved in 1 mL 
of PBS/EDTA buffer (pH 7.4, 5 mmole EDTA). To this solution, 0.80 mg of TCEP (2.80 µmole, 
20 equiv.) in 1mL of PBS/EDTA buffer (pH 7.4, 5 mmole EDTA) was added. The reaction 
mixture was evacuated, flushed with N2 and the reaction mixture was stirred for 15 minutes at 
room temperature under N2 to get the free thiolated conjugate. Then the reaction mixture was 
cool down to 0°C and 0.72 mg of EMCH (2.10 µmole, 15 equiv.) in 1 mL of PBS buffer was 
added. The reaction mixture was reacted for 3 hours at room temperature under N2. The reaction 
mixture was extensively dialyzed with water (dialysis membrane of molecular weight cutoff = 
1000 Da) for 24 hours and lyophilized to give EMCH functionalized G4 PAMAM-OH-PDP 
conjugate as a pale yellow oily solid. The EMCH functionalized G4 PAMAM-OH-PDP 
conjugate was characterized by proton NMR. 1H NMR (DMSO-d6, 400 MHz): δ (ppm) 8.90 (s, 
1H, hydrazide amide NH), 7.94 (bs, CO-NH, linker, G4-OH), 7.82 (bs, CO-NH, G4-OH), 4.8 
(bs, OH, G4-OH), 3.95 (m, CH2OCO), 3.50-2.00 (m, 997H, aliphatic protons of G4-OH, CH2 of 
linker, CH2CH2S CH CH2, NCH2, and NH2), 1.89 (m, CH2, methylene protons of linker, and 
CH2NHNH2), 1.58-1.32 (m, CH2, methylene protons of linker, and CH2NHNH2 of EMCH), 1.30-
1.05 (m, CH2, methylene protons of linker, and of EMCH). 
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Figure 23.  Synthesis of EMCH functionalized G4 PAMAM-OH-PDP as a model compound.  
3.3.7 Modification of ELISA Plate with PEG 
The solutions of EDC and HOBt in MES buffer (pH 6.5), 1mg/mL, were prepared. The 
amounts of 75 µL of EDC solution and 60 µL of HOBt solution were added to each well of 
ELISA plate (391 nmol of each per well). Then 10 µL of NH2-PEG-MeI (MW=3.4 kDa) in MES 
buffer (pH 6.5), 12.52 µg/mL, was added to each well (7.4 pmole/well) and incubated for 30 
minutes at room temperature. To each well 30 µL of NH2-PEG-OH (MW=2 kDa) was added, 
5.81 mg/well. The plate covered with aluminum foil and left to incubate for 8 hours at room 
temperature with constant shaking. Then ELISA plate was washed with PBS buffer (pH 7.4) 
three times and with deionized water three times, dried under nitrogen, and stored at -20 ˚C.  
3.3.8 Conjugation of G4 PAMAM-OH-PDP Dendrimer to Pegylated ELISA Plate  
G4 PAMAM-OH-PDP dendrimer (1.2 mg, 70 nmole) was dissolved in 1 mL of 
PBS/EDTA buffer (pH 7.4, 5 mmole EDTA). To this solution, 0.4 mg of TCEP (1.4 µmole, 20 
equiv.) in 0.5 mL of PBS/EDTA buffer (pH 7.4, 5 mmole EDTA) was added. The reaction 
mixture was evacuated, flushed with N2 and the reaction mixture was stirred for 15 minutes at 
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room temperature under N2 to get the free thiolated conjugate. Then the reaction mixture was 
transferred in glove box and cooled down to 0°C. To this 0.16 mg of EMCH (0.49 µmole, 7 
equiv.) in 0.5 ml of PBS buffer was added and incubated for 20 minutes at 0°C. The amount of 
10 µL of this reaction mixture was diluted to 31.5 mL with PBS buffer (pH 7.4) and 270 µL of 
diluted solution was added to each well of pegylated ELISA plate (3 pmole/well). The plate was 
sealed and incubated for 3 hours at room temperature in glove box with constant shaking. Then 
10 µL of 2-mercaptoethanol in PBS (pH 7.4) was added to each well (1 µL of 2-
mercaptoethanol/well) and incubated for 1 hour at room temperature. The ELISA plate was 
washed with PBS buffer (pH 7.4) four times and with deionized water four times, dried under 
nitrogen, and stored at -20 ˚C. 
3.3.9 Oxidation of Monoclonal Anti-Human TNF-α/TNFSF1 Antibody (MAB610) and Its 
Immobilization to Dendrimer Modified ELISA Plate 
 The oxidation was done by using sodium periodate. 500 µg of MAB610 was dissolved in 
1 mL of PBS (pH 7) buffer. To this 100 µL of NaIO4 solution in PBS (pH 7) added at 4˚C (5 µg 
NaIO4 per 50 µg MAB610). The reaction mixture left to react for 15 min at 4˚C protected from 
light. Then the reaction mixture was transferred to Amicon centrifuge filter tube and was 
centrifuged for 30 min, at 4˚C, and 2500 rpm. The concentrated sample, approximately 60 µL 
was diluted with PBS buffer (pH 7.4) to 1 mL and loaded to PD-10 column. The column was 
equilibrated with PBS (pH 7.4) according the spin protocol. Then the column was centrifuged at 
1000 G, and 4˚C for 2 min. The concentrated antibody was diluted to 11 mL with PBS buffer 
(pH 8), and 270 µL added to each well of dendrimer modified ELISA plate (3 µg/well). The 
ELISA plate was sealed and incubated for 3 hours at 4˚C with continuous shaking. Then 10 µL 
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of NaCNBH3 solution in PBS buffer (pH 8) (1mg NaCNBH3 per 1 mL buffer) was added to each 
well and incubated for 1 hour at 4˚C with continuous shaking. After 10 µL of ethanolamine 
solution in PBS buffer (pH 8) (1µL ethanolamine per 1 mL buffer) was added to each well and 
incubated for 30 min at 4˚C with continuous shaking. Antibody immobilized dendrimer modified 
ELISA plate then washed with wash buffer (WA126) seven times to make sure that there are no 
chemicals left. The plate dried by blotting it against clean paper towels. Then 300 µL of reagent 
diluents added to each well. The plate was sealed, covered by aluminum foil and left overnight at 
4˚C. Then the plate was washed again with wash buffer, dried in the same way as above and 
made ready for assay to be performed, which has to be done immediately.  
3.3.10 Assay Procedure  
The ELISA plate was washed with wash buffer seven times (300 µl per well).  Twelve 
different dilutions (concentrations from 460-0 pg/mL) of TNF-α standard in reagent diluents 
were prepared. 100 µL of each dilution were added per well in triplicate. The plate was sealed 
and incubated for 2 hours at room temperature. Then each well was washed with 300 µL wash 
buffer seven times. After the plate was dried by blotting it against clean paper towels, 100 µL of 
biotinylated antihuman TNF-a detection antibody (BAF 210, 1 µg/mL in reagent diluents) was 
added to each well. The plate was sealed and incubated for 2 hours at room temperature. The 
plate was washed and dried again in the same way as above and 100 µL of streptavidin-
horseradish peroxidase conjugate in reagent diluents was added to each well.  The plate was 
incubated for 30 min at room temperature avoiding light and washed again with wash buffer. 
Then 100 µL of substrate solution was added to each well and incubated 30 min in the dark at 
room temperature. To stop the color reaction 50 µl of stop solution (2N sulfuric acid) was added 
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to each well without washing the plate. The absorbance was measured immediately using a plate 
reader (Molecular Devices, SpectraMax M2) set at 450 and 570 nm.   
3.4 Results and Disscusion 
3.4.1 Synthesis of Bifunctional G4 PAMAM-OH-PDP Dendrimer 
Previously published results indicate that many commercially available ELISA plates 
have problem due to nonspecific protein adsorption.103 In order to reduce the non-specific protein 
adsorption and to improve the specificity and sensitivity of immunoassay technique, the 
hydroxyl-terminated G4-PAMAM dendrimer was used to prepare an assay platform for TNF-α 
cytokine detection. A bifunctional dendrimer was prepared by modifying few hydroxyl terminal 
groups of generation four PAMAM dendrimer (G4-OH) to reactive amine for this platform. The 
detailed synthetic procedure for this modification was reported by our group previously.104 In 
brief, the G4-OH was reacted with 5-Boc-amino-valeric acid to get Boc protected amine groups 
followed by deprotection with trifluoroacetic acid to generate a bifunctional dendrimer (2) 
having free amine groups on the surface. To be able to immobilize dendrimer on pegylated 
ELISA plate, the resulting bifunctional dendrimer was conjugated with linker N-succinimidyl 3-
(2-pyridyldithio)-propionate (SPDP) through amide bond (Figure 22). SPDP provides a protected 
thiol in the form of a disulfide bond. The conjugate was characterized by HPLC, proton NMR, 
and MALDI-TOF mass. HPLC gave very broad peak at 9.55 min due to large size and low 
polarity compared to starting dendrimers (Figure 24). The number of attached PDP groups to 
dendrimer was determined by NMR (Figure 25) by integrating peaks related to dendrimer amide 
and pyridyl hydrogens at 8.43 (d, 1H), 7.81 and 7.73 (m), and 7.22 (t, 1H) ppm. The integration 
revealed that 10 molecules of PDP were attached to the surface of the dendrimer. This is in a 
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good agreement with MALDI-TOF MS (Figure 26) which increased molecular weight indicates 
also that 10 molecules of PDP were added to dendrimer.  
 
Figure 24. HPLC chromatograms of G4-OH, bifunctional G4-OH-PDP dendrimer, and SPDP at 
210 nm.  
 
Figure 25. Proton NMR spectrum of G4 PAMAM-OH-PDP dendrimer in DMSO-d6. 
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Figure 26. MALDI-TOF mass spectra of (A) bifunctional G4 PAMAM-OH-PDP dendrimer, and 
(B) G4-OH dendrimer. 
 
The disulfide bond of PDP linker was reduced by tris(2-carboxyethyl) phosphine (TCEP) to thiol 
groups quantitatively.105 The resulting conjugate having free thiol groups was used in situ 
without purification and reacted with seven equivalence of N-(ε-maleimidocarproic 
acid)hydrazide (EMCH)  which is going to be used for antibody capturing.  The remaining thiol 
groups were required for dendrimer immobilization onto PEG-ELISA plate by conjugation to 
maleimide groups. In order to prove that thiol-maleimide conjugation reaction went through, a 
model reaction was performed (Figure 23).  Therefore, all the thiol groups were conjugated with 
EMCH to give hydrazide functionalized dendrimer. To prevent possible side reaction, the thiol-
maleimide conjugation reaction was carried out at 0°C. The structure of of EMCH functionalized 
G4 PAMAM-OH-PDP conjugate  was confirmed by 1H NMR (Figure 27), which shows 
characteristic hydrazide amide proton, NHNH2(C=O), at 8.90 ppm and no pyridyl hydrogens 
from PDP. 
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Figure 27. Proton NMR spectrum of EMCH functionalized G4 PAMAM-OH-PDP dendrimer. 
 
3.4.2 Surface Modification of ELISA Plate with PEG and Dendrimer Immobilization 
Due to nonspecific protein adsorption by commercially available ELISA plates, we 
modified our plates with polyethylene glycol (PEG). It is found that the nonspecific adsorption 
of proteins on the plate’s surface decreases with the increasing molecular weight of PEG chain. 
On the other hand, by increasing PEG molecular weight the tethered chain density decreases due 
to the exclusion volume of each chain on the surface.106 The ELISA plates were modified 
according to the procedure reported in our previous study.17 PEG was linked to the carboxylic 
acid functionalized 96 well polystyrene plates. The functionalization of polystyrene plate with 
PEG was carried out under mild conditions to minimize ring opening side reaction. Carboxylic 
acid groups of polystyrene plate were activated by EDC and 1-hydroxybenzotriazole hydrate 
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(HOBt), Figure 28. The resulting HOBt activated carboxylic groups could be hydrolyzed under 
desired mild conditions which minimized the ring-opening side reaction of the NH2-PEG-Mal.107 
PEG-maleimide (NH2-PEG-Mal, MW 3.4k Da) and PEG-hydroxyl (NH2-PEG-OH, MW 2k Da) 
were co-immobilized to improve the nonfouling character of the surface and also cover the 
‘defects’ on the polystyrene plate.103 NH2-PEG-Mal groups were used for immobilization of 
dendrimer. Two equivalents of NH2-PEG-Mal were reacted with activated carboxylic groups, 
based on the calculated dendrimer grafting density, considering the yield of the amidation 
reaction and the reduced reactivity of thiol-maleimide conjugation reaction in the presence of 
TCEP.105 Thus, NH2-PEG-Mal grafting density reflects the dendrimer graft density on the 
surface. 
 
Figure 28. Schematic representation of ELISA plate modification with PEG and immobilization 
of G4 PAMAM-OH-PDP dendrimer on PEG layer. 
 
Dendrimer immobilization was carried out inside the glove bag under the constant flow of 
nitrogen at 4°C for 3 hours. Then 2-thioethanol was added to react with unreacted maleimide 
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groups.  The dendrimer modified plates were washed, dried, and stored at -20°C. They can be 
stable for several months with no signs of reduced reactivity, suggesting that the dendrimer-
modified plates are stable and have an appreciable life time. 
 
3.4.3 Antibody Immobilization onto Dendrimer Modified ELISA Plate 
Antibodies play a key role in diagnostic methods; therefore the way in which they are 
immobilized is very important. Antibodies are proteins, also called immunoglobulins (Ig), 
because they are related to the immunological system. Basically they are glycoproteins having 
carbohydrate chains added to some of their amino acid residues. The amounts of carbohydrates 
can vary (3-12%) depending on the type of antibody and they are attached to the protein through 
N-linked glycosylation site. Most glycosylation sites are located in constant region (Fc) of the 
heavy chain. Glycosylation of these sites has little if any effect on binding activity of 
antibodies.108 The studies showed that steric-hindrance, denaturation of antibody, and its random 
orientation lead to reduction of binding activity of an antibody.109 By controlling the orientation 
of immobilized antibodies on the sensor surface and with decreasing steric-hindrance effects, 
specificity and sensitivity of an immunosensor can be increased.  
The efficacious antigen binding depends on antibody immobilization method. Currently 
available methods often have disadvantages such as reduced antibody-antigen binding activity 
mostly due to random antibody orientation, denaturation, or steric-hindrance.110 The easiest 
method of antibody immobilization is adsorption on a solid surface. However, adsorbed 
antibodies are randomly oriented and their antigen binding activity can be reduced due to 
denaturation. The most common method for antibody immobilization is covalent coupling using 
amino groups on antibody surface.  The disadvantage of this method is random orientation that 
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leads to nonspecific binding. Some methods employ chemical immobilization of the antibodies 
by chemically modifying the carbohydrates on the Fc region of an antibody or selectively 
reducing disulfide bond of the cysteine residue in the hinge region of the antibody. Other 
methods use protein G and protein A for orientated immobilization that specifically bind to the 
Fc region of an antibody. These methods are less stable than covalent methods.  
Mouse anti-human TNF-α antibodies were immobilized by their oligosaccharide moieties 
in the constant region to dendrimer hydrazide linker of modified ELISA plate following similar 
procedure that we used for IL-6 and IL-1β immobilization (Figure 29).17  
 
Figure 29. Schematic representation of antibody immobilization on the ELISA plate modified 
with multifunctional dendrimer. 
 
First, carbohydrate vicinal hydroxyl groups in the constant region of antibody were oxidized by 
sodium periodate in PBS buffer (pH 7) to aldehyde groups.  The number of oxidized sites 
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generated by NaIO4 depends on pH, temperature, reaction time and the concentration of the 
oxidizing reagent.111 Using Purpald test with formaldehyde as a calibrator, we examined the 
degree of antibody oxidation (Figure 30).112 Mild oxidation conditions were chosen to preserve 
the immunoreactivity of the antibody:  50 µg of MAB610 antibody in PBS pH 6.8 was oxidized 
by 0.1 mg NaIO4 (0.47 mM) for 15 minutes at 4°C in the dark.  According to Purpald test, under 
these conditions, approximately 8 aldehyde groups per antibody were obtained.  
 
 
Figure 30. Standard curve of formaldehyde purpald test. 
The aldehyde groups are required for the reaction with dendrimer hydrazide end group to form 
hydrazone linkage. After oxidation, antibody was quickly separated from the oxidizing reagent 
by the Amicon® centrifugal filter tube, and gel filtration with concomitant buffer exchange. The 
purified oxidized antibody was dissolved in PBS buffer pH 8 and allowed to react with 
dendrimer on ELISA plate at 4ºC for 3 hours, where hydrazone Schiff base was obtained. 
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Because Schiff base is unstable, in situ reductive amination with sodium cyanoborohydride in 
PBS buffer pH 8 was performed and hydrazone linkage was transformed into a stable secondary 
amine linkage.113 The reaction was completed by adding ethanolamine to block unreacted al-
dehyde groups. 
3.4.4 ELISA evaluation of dendrimer-modified surface 
To evaluate the diagnostic performance of the dendrimer-based assay, recombinant 
human TNF-α were assayed by the sandwich ELISA format using biotinylated goat anti-human 
TNF-α as detection antibodies, streptavidin-HRP as a reporter and substrate tetramethylbenzidine 
(TMB), Figure 31.  Various known standard concentrations of TNF-α in the range of 0-250 
pg/mL were assayed and typical dose-response curve was acquired. The reaction time between 
antibodies on the sensor and the cytokines was 2 hours, and was the same as that for the kit plate. 
These data were compared with commercially available TNF-α ELISA kit, and a plate coated 
with mouse anti-human TNF-α capture antibodies, which were attached by physical adsorption 
(Figure 32).  
The linear regression equation for dendrimer plate for TNF-α was A = 0.1502 + 
0.0037*C[TNF-α], with the linear regression coefficient R = 0.996.  The sensitivity of dendrimer 
plate for TNF-α detection (TMB) was determined to be 0.48 pg/mL (Table 3). Various methods 
have been developed for determination of TNF-α level including ELISA, RIA,82 bioassays,83 
chemiluminescence84 and chemiluminescence imaging,85 MALDI-MS,86 immuno-PCR87 and 
immuno-PCR assay,88 fluorescence immunoassay,89 and electrochemical immunosensor90. 
Dendrimer based assay in present study has a detection limit superior to that of other previously 
reported TNF-α assay except that obtained by Hun et al. which used fluoroimmunoassay method. 
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Figure 31. Schematic representation of TNF-α assay using dendrimer modified ELISA plate. 
 
 
Figure 32. Standard curves for TNF-α ELISA measured with the dendrimer plate, TNF-α kit 
plate, and the plate prepared by physical adsorption of antihuman TNF-α antibody. 
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Dendrimer modified plate showed ~3 fold improvements on the detection limit compare to kit 
plate for TMB detection (0.48 pg/mL vs. 1.28 pg/mL). This result suggests that dendrimer 
conjugation reactions to the antibody preserved the activity of the antibody and the dendrimer-
based assay performed better than the commercially available ELISA kit for TNF-α. Compared 
to physical adsorption, the dendrimer plate showed significant improvement in detection limit 
(0.48 pg/mL vs 8.00 pg/mL) which is 17 times better (Table 3). 
Table 3.  TNF-α ELISA data obtained from dendrimer plate, and plate prepared by physical 
adsorption, TMB detection 
TNF-α 
Conc. 
(pg ml-1) 
Dendrimer 
Plate 
       (O.D.) 
TNF-α Conc. 
(Cytok. mix.) 
(pg ml-1) 
Dendrimer 
Plate 
(O.D.) 
TNF-α 
Conc. 
(pg ml-1) 
Physical 
Adsorption 
(O.D.) 
TNF-α 
Kit 
(O.D.) 
300 
240 
80 
26.6 
8.88 
2.96 
0.98 
0.32 
0.11 
0.037 
0 
R² 
1.213 
1.067 
0.493 
0.270 
0.192 
0.151 
0.137 
0.143 
0.141 
0.136 
0.138 
0.996 
300 
240 
80 
26.6 
8.88 
2.96 
0.98 
0.32 
0.11 
0.037 
0 
1.048 
0.800 
0.423 
0.262 
0.188 
0.171 
0.164 
0.169 
0.158 
0.160 
0.164 
0.995 
500 
250 
125 
62.5 
31.2 
15.6 
7.5 
3.75 
1.87 
0.94 
0 
1.928 
1.440 
1.018 
0.884 
0.804 
0.705 
0.646 
0.662 
0.618 
0.640 
0 
0.980 
1.287 
0.6625 
0.3335 
0.2045 
0.107 
0.0655 
0.047 
0.042 
0.035 
0.0335 
0.0315 
0.998 
 
LLDa 0.15  0.17  0.68 0.034 
Sensitivity 
(pg ml-1) 
<0.48  <1.14  <8 <1.28 
a
 The lower limit of detection (LLD) of TNF-α was determined by adding two STD to the mean 
OD of three zero standard replicates and calculate the corresponding concentration from the 
standard curve. 
 
The sensitivity was obtained from standard curves (Figure 32) as a slope versus 
concentration. Compared to kit plate the slope of the dose–response curve for dendrimer plate 
(0.0037 versus 0.0027) was steeper, which can be explained by the enhanced binding efficiency 
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of the antibodies immobilized on the dendrimer plate. We also performed chemiluminescence 
assay (data not shown) for both dendrimer plate and ELISA kit for TNF-α and we found that the 
sensitivity was similar to colorimetric assay. This is in an agreement with literature data that the 
chemiluminescence method may not give improved sensitivity for every cytokine.114  
To assess the overall specificity of the dendrimer-based immunosensors toward TNF-α detection, 
the mixture of cytokines was prepared and studied with the dendrimer-modified ELISA plate. 
The standard solution containing 300 pg/mL of each of the following: TNF- α, IL-1α, and IL-6 
was used to prepare dilutions in the range of 0-250 pg/mL. The selectivity of the dendrimer 
modified ELISA plate was examined. No significant difference of OD was observed in 
comparison with the result obtained in the presence of only TNF-α (Figure 32). 
The precision and reproducibility of the dendrimer plate was determined by calculating 
the relative standard deviation (RSD) for three zero standard replicates and coefficient of 
variation (CV) for both intra-assay and inter-assay variability, respectively. For immunoassays 
such as ELISA, intra- or inter-assay variability should be lower that 8–15 % to be considered 
precise enough for its use. In our case the plate had good precision with RSD of 5.4 %. CV for 
intra-assay variability was calculated between OD values of triplicates within each run of two 
independent assay runs, for each dilution concentration, and it ranged between 0.09 and 13.0 %. 
The inter-assay variability was determined by calculating the CV between OD values obtained 
from two triplicates of independent assay runs, and it ranged between 2.08 and 13.39 %. This 
indicates that the assays on dendrimer modified plates are reproducible. 
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3.5 Conclusions 
TNF-α is important cytokine in a variety of inflammatory diseases, and is a marker for 
chorioaminionitis. The ability to measure accurately and precisely very low concentrations of 
TNF-α is very important. In this work the dendrimer based biosensor platform was used for 
detection of TNF-α cytokine. Thiol functionalized G4-OH dendrimers were covalently 
immobilized onto maleimide-terminated PEG ELISA plate. The dendrimer modified ELISA 
plate was reacted to oxidized antibody by coupling the hydrazide groups of dendrimer and 
aldehyde groups of oxidized antibody. In this way the capture antibody has favorable orientation 
of the antigen binding sites toward the analyte phase. The dendrimer-based capture of TNF-α 
shows a detection limit of 0.48 pg/mL for TMB detection, which is significantly better than the 
commercial ELISA kit for TNF-α. The dendrimer based diagnostic nanodevice proved to have 
improved sensitivity and specificity and can be used for the detection of a wide range of 
cytokines and biomarkers. 
3.6 Future Work 
3.6.1 Detection of Pro-inflammatory Cytokines in Human Samples 
An elevated level of pro-inflammatory cytokines such as TNF-α, IL-6, IL-1β, and MMP-
8 are found in infected intra-amniotic fluid of a pregnant woman. Early detection of these 
cytokines is very important to prevent preterm labor. In order to assess the accuracy and 
applicability of dendrimer-based assays the cytokine detection can be done using human serum 
samples from normal (nonpregnant) and infected women and compared to commercially 
available kits. 
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CHAPTER 4 “SYNTHESIS AND CHARECTERIZATION OF DENDRIMER-
PROGESTERON METABOLITE CONJUGATES FOR TRAUMATIC BRAIN INJURY 
TREATMENT” 
4.1 Abstract 
 Progesterone, a steroid hormone, and its metabolite allopregnanolone are potential 
neuroprotective agents following traumatic brain injury (TBI). The therapeutic use of 
progesterone is limited due to its poor solubility and stability. This can be much improved using 
dendrimers as delivery vehicles. In this study poly(amidoamine) (PAMAM) dendrimer-
allopregnanolone nanodevices are designed for TBI treatment. Two conjugates have been 
synthesized, dendrimer-allopregnanolone and dendrimer-allopregnanolone isomer, and 
characterized by proton NMR, HPLC and MALDI-TOF mass spectroscopy. Release study of 
dendrimer-allopregnanolone isomer showed no drug release in PBS buffers with varios pH (7.4, 
4.6, and 1.4) due to short spacer between the drug and dendrimer. Based on this, dendrimer-
allopregnanolone conjugate was prepared by putting longer spacer between drug and dendrimer. 
Allopregannaolone released from the conjugate in PBS buffer pH 2.1 in a sustained manner. The 
realase was evaluated by reverse phase HPLC (RP-HPLC) analysis, and 90% of drug payload 
was released within 9 days. In future study, the pharmacological activity of dendrimer-
allopregnanolone conjugate, by measuring the inhibition of prostaglandin secretion, will be 
evaluated in vitro using A 549 lung epithelial cells. 
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4.2 Introduction 
Traumatic brain injury (TBI) occurs when an external force traumatically injures the 
brain. It is a significant public health problem that affects nearly 1.5 million Americans each year 
resulting in more than 50,000 deaths.115 Initially TBI causes ionic imbalances, oxidative damage, 
microglial activation, immune cell invasion, and cytokine release.116,117 This can result in 
cerebral edema, inflammation, tissue necrosis, apoptosis, etc. No matter which factors initiate the 
injury cascade, the inhibition of inflammation may reduce cell death, gliosis, and edema.118,119  
Currently there are no treatments that improve clinical outcome measures. The research findings 
have shown that the progesterone and its reduced metabolite allopregnanolone, (5α -pregnane-
3α-ol, 20-one or 5α -tetrahydroprogesterone) may be promising therapeutics for TBI treatment 
(Figure 33).120,121 Progesterone is a steroid hormone involved in female menstrual cycle, 
pregnancy, and embryogenesis of humans and other species. It belongs to the group of 
neurosteroids. Progesterone is produced by the adrenal glands, the corpus luteum, as well by 
neurons and glial cells within the central and peripheral nervous system.122  Progesterone showed 
several different modes of neuroprotection following TBI, including the reduction of cerebral 
edema,123 the reduction of lipid peroxidation and oxidative stress,124  anti-inflammatory 
effects,118 reduction of cellular apoptosis,125 inhibition of excitotoxicity,126 and helps myelin 
repairement.122,127 Progesterone has also neuroactive properties that can modulate neuronal 
excitability and seizure activity.128,129 There are two mechanisms engaged in neuroprotective 
effects of progestrone: binding to progesterone receptors (PRs) and its metabolite to GABA-A 
receptor modulating neurosteroids.131,133 Progesterone binding to cytoplasmic PRs of target cells 
leads to the formation of the hormone-nuclear receptor complexes to translocate to the cell 
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nucleus where they activate or stop the transcription of downstream gene networks, therefore 
affect the physiological response of progesterone-responsive target cells.131 However, numerous 
studies have showed that the antiseizure effects of progesterone do  not directly result from 
interactions with classical PR. These studies support the idea that 5α-reduced metabolites of 
progesterone, predominantly allopregnanolone, are responsible for the seizure 
protection.128,130,131 Allopregnanolone is synthesized from progesterone via two sequential A-ring 
reductions both in peripheral tissues and in the brain. It binds to a steroid-binding site on the 
GABA-type A (GABAA) receptor, and potentiates its function leading antiseizures effects. It is 
assumed that GABA-A receptors are pentameric with five protein subunits that form the chloride 
ion channel pore. GABA-A receptors are mostly composed of α, β and γ or δ subunits. 
Allopregnanolone has unique binding site on GABA-A receptors. Even though that binding of 
allopregnanolone to PRs is poor, it could indirectly activate PRs by re-conversion to 
dihydroprogesterone that is a moderately potent PR agonist. Progesterone and neurosteroids also 
affect GABA-A receptor expression. Therefore, there may be an interaction between genomic 
and non-genomic actions of progesterone that are involved in seizure protection. 131 
Allopregnanolone plays a variety of neurprotective roles during gestation. It also showed 
improved seizure control in women suffering from catamenial epilepsy.128,131  
 
Figure 33. Chemical structures of progesterone and its metabolite allopregnanolone. 
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Due to their exceptional properties dendrimers are emerging as potential nanoscale 
delivery vehicles.  They are nearly monodisperse, tree-like polymers with a large density of 
tailorable, functional end groups. Dendrimers have ability of conjugation, complexation, and 
encapsulation of multifunctional moieties.2 In this study hydroxyl terminated PAMAM 
dendrimers are being explored as drug delivery vehicles for TBI treatment. Two conjugate 
nanodevices were synthesized: PAMAM dendrimer-allopregnanolone 3β,5β-isomer and 
PAMAM dendrime-allopregnanolone. The isomer of allopregnanolone has been modified to its 
succinate by reacting to succinic anhydride and conjugated directly to poly(amidoamine) 
dendrimer (PAMAM) through an ester bond. However the allopregnanolone was modified to 
allopregnanolone succinate and conjugated to bifuctional dendrimer through and amide bond. 
Bifuctional dendrimer was prepared by reaction of hydroxyl-terminated poly(amidoamine) 
dendrimer (G4-OH) to a protected amine linker followed by deprotection. The role of the linker 
on the dendrimer is to help the drug release in a resonable manner. Coupling the drugs to 
dendrimer the solubility and stability limitations of progesterone, as well as multistep enzymatic 
synthesis of allopregnanolone will be avoided. This approach will allow for dose reduction 
leading to fewer side effects and based on targeting ability of dendrimers the efficacy of the drug 
is expecting to be increased.  
4.3 Materials and Methods 
4.3.1 Materials 
Hydroxyl terminated G4-PAMAM dendrimer (G4-OH) was purchased from Dendritech®, 
Inc. (Midland, MI).  DMSO-d6 and CDCl3 was purchased from Cambridge Isotope Laboratories. 
Benzotriazol-1-yl-oxytripyrrolidinophosphonium hexafluorophosphate (PyBOP), K-Selectride 
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1M in THF, 5-(tert-butoxycarbonyl-amino)butyric acid, sodium borohydride, succinic anhydride, 
pyridine, diisoprophylethylamine (DIEA),  and MALDI-MS reference standards were purchased 
from Sigma-Aldrich. Triethylamine (TEA) and ethylene diamine (EDA) were purchased from 
Thermo Scientific. Palladium, 5% on calcium carbonate, was obtained from Alfa Aesar, MA, 
USA. Sodium hydroxide was obtained from Fisher Scientific. Trifluoroacetic acid (TFA) was 
purchased from EMD. Anhydrous DMSO, dichloromethane (DCM), and tetrahydrofuran (THF) 
were purchased from Acros Organics, USA. All other solvents and chemicals used were 
purchased from Fisher Scientific. Regenerated cellulose (RC) dialysis membrane with molecular 
weight cut-off of 1000 Da was obtained from Spectrum Laboratories. 
4.3.2 Characterization 
NMR spectra were recorded on a Varian INOVA 400 spectrometer using commercially 
available deuterated solvents. Proton chemical shifts are reported in ppm (δ) and 
tetramethylsilane (TMS) used for internal standard. ESI mass spectra were recorded on Waters 
Micromass ZQ spectrometer. Matrix-assisted laser desorption ionization-time of flight (MALDI-
TOF) mass spectra were recorded on a Bruker Ultraflex system equipped with a pulsed nitrogen 
laser (337 nm), operating in positive ion reflector mode, using 19 kV acceleration voltage and a 
matrix of 2,5-dihydroxybenzoic acid. Cytochrome C (MW 12,361 g/mol), and Apomyoglobin 
(MW 16,952 g/mol) were used as external standards. A dendrimer solution was prepared by 
dissolving 2 mg of dendrimer in 1 mL of DMSO. The matrix solution was prepared by 
dissolving 20 mg of matrix in 1 mL of the 1:1 mixture of deionized water and acetonitrile (0.1% 
TFA). Analytical samples were prepared by mixing 10 µL of dendrimer solution with 100 µL of 
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matrix solution, followed by deposition of 1 µL of sample mixture onto a 384-well aluminum 
plate. This mixture was allowed to air dry at room temperature. 
4.3.3 High performance liquid chromatography (HPLC) 
HPLC characterization was carried out using Waters HPLC instrument equipped with 
dual pumps, an auto-sampler and dual UV detector interfaced to Breeze software. The HPLC 
chromatogram was monitored at 210 and 205 nm simultaneously using the dual UV absorbance 
detector. H2O:ACN (0.14 % TFA) was used as mobile phase. Both phases were freshly prepared, 
filtered, and degassed prior to use. Symmetry300 C18 reverse-phase column (5 µm particle size, 
25 cm × 4.6 mm length × I.D.) equipped with a Supelguard Cartridges (5 µm particle size, 2.0 
cm ×3.9 mm length × I.D.) was used for characterization of the conjugates. HPLC analysis was 
done using 90:10 to 10:90 (H2O:ACN) gradient flow in 30 minutes with flow rate of 1 mL/min.  
4.3.4 Release Study Protocol 
The release studies were performed in 0.1M PBS buffer solution pH 7.4, 0.1 M citrate 
buffer pH 4.6, and 0.1 M hydrochloric acid buffer pH 2.1. The conjugates were added into 3 mL 
preheated buffer solutions in triplicates. All the release solutions containing 3.0 mg/mL 
dendrimer drug conjugates were stirred continuously and maintained at 37ºC. At appropriate 
time intervals samples were withdrawn and immediately analyzed by HPLC to determine the 
drug concentrations. 
4.3.5 Synthesis  
4.3.5.1 5β Reduction Product of Progesterone  
The reaction scheme is outlined in Figure 34. Progesteron (1.00 g, 3.18 mmole) was 
dissolved in 66 mL absolute ethanol in a round bottom flask, and KOH (0.180 g) and 5% 
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Pd/CaCO3 (0.090 g) were added. The flask was evacuated, flushed with hydrogen and the 
reaction mixture stirred for 1 hour. The ethanol was removed and the residue was redissolved in 
ether and washed with water. The water layer was extracted with ether twice. The aqueous layer 
was then acidified to pH<3 with 1M HCl and extracted with ether. The organic layers were 
combined, dried, filtered, and concentrated to give crude 5β reduction product. The pure 5β 
reduction product was isolated by flash column chromatography on silica gel using ethyl 
acetate/hexanes (1:5) as mobile phase (0.60 g, yield 60%); Rf = 0.16 (1:5 ethylacetate /hexanes), 
and it was characterized by proton NMR. 1H NMR (CDCl3) δ 2.66 (t, 1H, J = 15 Hz), 2.53 (t, 
1H, J = 9.0 Hz), 2.34 (dt, 1H, J 14.4, 5.4 Hz), 2.21-1.09 (m, 20H), 2.12 (s, 3H), 1.02 (s, 3H), 0.64 
(s, 3H). ESI MS (m/z): calcd for C21H32NO2 [M+H]+ 317.2481, found 317.2471.  
 
Figure 34. Synthesis of 3β,5β allopregnanolone isomer from progesterone.  
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4.3.5.2 Allopregnanolone Isomer  
 The reaction pathway is shown in Figure 34. The pure 5β reduction product (0.849 g, 
2.68 mmole) dissolved in dry THF (5 mL) under nitrogen atmosphere and cooled down to 78°C. 
To this 3.22 mL of K-Selectride was added. The reaction mixture was stirred for 1.5 hours at 
78°C, and 1 hour at 0°C. Then 7 mL of 10% NaOH and 5 mL of 30% H2O2 added followed by 
overnight stirring at room temperature. The product was extracted by ethylacetate three times.  
Organic layers combined and washed with water two times, sodium bisulfate two times and brine 
two times, dried over NaSO4 and evaporated under reduced pressure. The pure product, of 3β, 
5β-tetrahydroprogesterone was isolated by flash column chromatography on silica gel using 
ethylacetate/hexanes (1:3) as mobile phase (0.765 g, yield 90%); Rf = 0.28 (1:3 ethyl acetate 
/hexanes), and it was characterized by proton NMR. 1H NMR (CDCl3) δ 4.091 (t, 1H), 2.499 (t, 
1H), 2.200 - 1.000 (m, 23H), 2.081 (s, 3H), 0.930 (s, 3H), 0.568 (s, 3H). ESI MS (m/z): calcd for 
C21H35O2 [M+H]+ 319.2637, found 319.2630..  
4.3.5.3 Allopregnanolone Isomer Succinate (3β, 5β-tetrahydroprogesterone Succinate) 
The reaction scheme is shown in Figure 35. Succinic anhydride (383.95 mg, 3.8364 
mmole) and DMAP (78.08 mg, 0.6394 mmole) added to a solution of 3α, 5β-
tetrahydroprogesterone (203.00 mg, 0.6394 mmole) in pyridine. The reaction mixture stirred 
under N2 and 45°C and monitored by TLC plate until its completion. After 24 hours the reaction 
stopped, and the solvent was evaporated. The crude product was redissolved in dichloromethane 
and washed with water. The water layer was washed three times with dichloromethane. Organic 
layers combined and washed with water and brine, dried over NaSO4 and evaporated under 
reduced pressure. The pure product was isolated by flash column chromatography on silica gel 
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using ethylacetate/hexanes (2:3) as mobile phase (214 mg, yield 80%); Rf = 0.35 (2:3 ethyl 
acetate /hexanes), and it was characterized by proton NMR. 1H NMR (CDCl3) δ 5.092 (t, 1H), 
2.556-2.700 (m, 4H linker), 2.087 (s, 3H), 2.000-1.000(m, 23H), 0.934 (s, 3H), 0.576 (s, 3H). 
ESI MS (m/z): calcd for C21H37O5 [M-H]+ 417.2641, found 417.2652. 
 
Figure 35. Synthesis of G4-OH PAMAM – allopregananolone isomer nanodevice. 
 
4.3.5.4 Allopregnanolone Succinate (3α, 5α-tetrahydroprogesterone Succinate) 
 Allopregnanolone succinate was prepared in the same way as allopregananolone isomer 
succinate. Pure product was isolated by flash column chromatography and characterized by 
proton NMR . 1H NMR (CDCl3) δ 5.027 (t, 1H), 2.600-2.700 (m, 4H linker), 2.505 (t, 1H), 2.124 
(m, 1H), 2.095 (s, 3H), 1.970 (m,1H) 1.750-1.080(m, 19H), 0.926 (m, 1H), 0.766 (m, 1H) 0.766 
(s, 3H), 0.582 (s, 3H). 
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4.3.5.5 G4-OH PAMAM – Allopregnanolone Isomer Nanodevice 
 The reaction scheme for the preparation of the conjugate is outlined in Figure 35. The 
allopregnanolone isomer-succinate (52.0 mg, 0.1242 mmole) dissolved in DMF (1 mL) and 
cooled down to 0°C using ice water bath. To this PyBOP (96.0 mg, 0.1863 mmole) dissolved in 
DMF (1 mL) and DIEA (32.54 µL, 0.1863 mmole) added under nitrogen atmosphere. Ice water 
bath removed and the mixture stirred for 1 hour at room temperature. Then PAMAM G4-OH 
(113.0 mg, 0.0079 mmole) dissolved in DMF (2 mL) added to the reaction mixture. The reaction 
stirred for 48 hours at room temperature. The resulting solution dialyzed extensively with DMF 
(dialysis membrane of molecular weight cutoff = 1000 Da) for 24 h. The obtained reaction 
mixture lyophilized yielding G4-OH PAMAM-allopregnanolone isomer conjugate with ester 
linker. The conjugate was characterized by proton NMR. 1H NMR (DMSO-d6, 400 MHz): δ 
(ppm) 8.048 (bs, CO-NH, linker), 7.939 (bs, CO-NH, G4-OH), 7.783 (bs, CO-NH, G4-OH), 
4.298 (t, 1 H, Allo-iso), 4.715 (bs, OH, G4-OH),  3.989 (m, CH2OCO, G4-OH), 3.37-2.16 (m, 
984 H aliphatic protons, G4-OH; 4 H CH2, linker; 28 H, Allo-iso), 2.034 (s, 3 H, Allo-iso-CH3) 
2.000-1.000 (m, 23H, Allo-iso), 0.895 (s, 3H, Allo-iso-CH3), 0.482 (s, 3 H, Allo-CH3). 
4.3.5.6 G4-OH PAMAM – Allopregnanolone Nanodevice 
 The reaction scheme is shown in Figure 36. Allopregnanolone-succinate (22.0 mg, 
0.0526 mmole) dissolved in DMF (1 mL) and cooled down to 0°C using ice water bath. To this 
PyBOP (41.0 mg, 0.0788 mmole) dissolved in DMF (1 mL) and DIEA (15.0 µL, 0.0788 mmole) 
added under nitrogen atmosphere. Ice water bath removed and the mixture stirred for 1 hour at 
room temperature. Then bifuctional PAMAM dendrimer (100.0 mg, 0.0066 mmole) dissolved in 
DMF (2 mL) added to the reaction mixture. The reaction stirred for 48 hours at room 
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temperature. The resulting solution dialyzed extensively with DMF (dialysis membrane of 
molecular weight cutoff = 1000 Da) for 24 h. The obtained reaction mixture lyophilized yielding 
G4-OH PAMAM-link-allopregnanolone conjugate. The conjugate was characterized by proton 
NMR. 1H NMR (DMSO-d6, 400 MHz): δ (ppm) 8.042 (bs, CO-NH, linker), 7.931 (bs, CO-NH, 
G4-OH), 7.770 (bs, CO-NH, G4-OH), 4.853 (t, 1 H, All), 4.705 (bs, OH, G4-OH),  3.977 (m, 
CH2OCO, G4-OH), 3.40-1.90 (m, 984 H aliphatic protons, G4-OH; 4 H CH2, linker; 6 H, Allo), 
1.750-1.080 (m, 19 H, Allo), 0.833 (m, 1 H, Allo), 0.727 (s, 3H, Allo-CH3), 0.482 (s, 3 H, Allo-
CH3). 
 
(HO)59 O
O
H
N
G4
O
H
HH
O
H
O
O 5
O
H
HH
O
H
O
O
HO
O
H
HH
HO
H
+
Pyridine
DMAP
45oC overnight
O
O
O
Allopregnanolone succinateAllopregnanolone
(HO)59 O
O
NH2
G4
5
Allopregnanolone succinate
PyBOP, DIEA
DMF,rt, 48h
 
Figure 36. Synthesis of dendrimer-allopregananolone nanodevice. 
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4.4 Results 
4.4.1 Synthesis of Nanodevices 
G4-OH-Allopregnanolone Isomer Nanodevice. The nanodevice was prepared by coupling 
reaction of G4-OH dendrimer with allopregnanolone isomer succinate. Since allopregnanolone is 
a quite expensive compound (Sigma – Aldrich sells 10 mg for $159.50), for preliminary studies 
the isomer of allopregnanolone was synthesized from progesterone following already published 
procedures (Figure 34).134,135 Hydrogenation of progesterone in the presence of hydroxides is 
known to provide 5β reduction product. Treatment of 5β reduction product with K-Selectride in 
dry THF leads to selective reduction of the C-3 carbonyl in the presence of the C-20 ketone 
giving allopregnanolone isomer (or 3β, 5β-tetrahydroprogesterone) product. Then reaction of 
allopregnanolone isomer with succinic anhydride produces a succinate having a carboxylic group 
required for the coupling reaction to dendrimer. All three compounds are charectirized by mass, 
proton NMR, and HPLC. The HPLC chromatograms showed that the retention times for 
allopregananolone isomer, 5β reduction product of progesterone, and allopregnanolone isomer 
succinate were 25.50, 26.00 and 26.23 min respectively (Figure 37). The allopregnanolone 
isomer succinate was conjugated to dendrimer using an ester link for ‘slow drug release’. The 
specific steps of the synthesis of allopregnanolone isomer-dendrimer nanodevices, is shown in 
Figure 35. Brifely, the nanodevices was obtained by coupling hydroxyl terminated generation 4 
PAMAM dendrimer with allopregnanolone isomer succinate using PyBOP (as a coupling agent) 
in the presence of catalytic amount of DIEA in DMF. The resulting conjugate was purified by 
dialysis in DMF, lyophilized, and charectirized using NMR, MALDI-TOF MS, and HPLC.  
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Figure 37. HPLC chromatograms of G4-OH (red), G4-OH-allopregnanolone isomer conjugate 
(blue), allopregananolone isomer (light blue), 5β reduction product of progesterone (green), and 
allopregnanolone isomer succinate (black) 
 
The HPLC spectra showed that the conjugate G4-OH-allopregnanolone isomer gave very 
distinct broad peak at 18.9 min compared to G4-OH dendrimer that gave a peak at 7.2 min 
(Figure 37). The proton NMR of G4-OH-allopregnanolone isomer conjugate is shown in Figure 
38. Comparison of the integration of amide peaks of dendrimer and methyl groups of 
allopregnanolone revealed that three molecules of allopregnanolone isomer were attached to the 
surface of the dendrimer.  
MALDI-TOF MS spectra of G4-OH-allopregnanolone isomer conjugate is shown in 
Figure 39. The obtained molecular weight of G4-OH-allopregnanolone isomer (15,686.4) 
compared with G4-OH (13,949.5) suggests that a payload of approximately three to four 
molecules of allopregnanolone isomer was achieved. This represents a drug payload in the 
conjugate of ~8% by weight. The conjugate was soluble in PBS buffer pH 7.4, compared to the 
free allopregnanolone isomer which is not. 
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Figure 38. Proton NMR spectrum of dendrimer-allopregnanolone isomer conjugate in DMSO-
d6. 
 
 
Figure 39. MALDI-TOF MS spectra of G4-OH PAMAM-allopregananolone isomer conjugate. 
82 
 
G4-OH-Link-Allopregnanolone Nanodevice. For the synthesis of this nanodevice a 
bifuctional dendrimer was used to improve the drug release from dendrimer by putting an 
additional spacer between drug and dendrimer, Figure 36. The bifunctional dendrimer was 
prepared by reacting 4-Boc-amino-butyric acid, as a linker to provide protected NH2 groups, and 
G4-OH hydroxyl terminated dendrimer followed by deprotection of Boc protected amine groups. 
Based on proton NMR and and MALDI-TOF mass (not shown here) there are approximately 5-6 
amine groups added.  Then bifuctional dendrimer was reacting to allopregnanolone succinate to 
obtain G4-OH-link-allopregnanonolone conjugate. The conjugate was thoroughly characterized 
by proton NMR (Figure 40), HPLC (Figure 41), and MALDI-TOF mass (Figure 42).  Based on 
proton NMR and MALDI-TOF mass analyses five molecules of allopregnanolone were attached 
to dendrimer giving the drug payload ~10% by weight. 
 
Figure 40. Proton NMR spectrum of dendrimer-allopregnanolone conjugate in DMSO-d6. 
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Figure 41. HPLC chromatograms of G4-OH, bifuctional dendrimer, G4-OH-link-
allopregnanolone conjugate, and allopregnanolone at 205 nm. 
 
 
 
Figure 42. MALDI-TOF MS spectra of G4-OH PAMAM-allopregananolone conjugate. 
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4.4.2 Release Studies 
In vitro drug release rate from dendrimer-drug nanodevices were carried out at various 
pH values at 37°C and analyzed by HPLC at 205 nm. The drug release rate of G4-OH-
allopregananolone isomer nanodevice was studied at pH 2.1, 4.6, and 7.4 and HPLC analysis 
showed no drug release from conjugate. The stability of ester linkages of the G4-OH-
allopregananolone isomer nanodevice could be attributed to the size and chemical structure of 
the spacer between the drug and dendrimer as well as steric effect caused by dendrimer structure. 
To increase the drug release kinetics, G4-OH-link-allopregnanolone nanodevice was designed. 
The design consisted of the conjugation of allopregnanolone having succinic acid linker with 
bifuctional dendrimer (G4-OH dendrimer having several linkers with end amine groups) giving 
G4-OH-link-allopregnanolone nanodevice. In this case the spacer was longer and had peptide 
link and resulted in successful drug release from dendrimer. The drug release rate of this 
nanodevice was studied in hydrochloric acid buffer pH 2.1 and HPLC analysis showed that the 
nanodevice was susceptible to hydrolysis and about 90% of the drug was released within 9 days 
(Figure 43). HPLC chromathogram cleary showed the appereance of the drug peak and peak of 
the bifuctional dendrimer with the time (not shown here). This indicates that the hydrolytic 
cleavage of ester bond on the dendrimer’s side is quite stable. The release rate of 
allopregnanolone appears to be following first order reaction kinetics. The logarithmic equation 
was fitted to the release profile as shown in Figure 43. The equation fits fairly well and this 
indicates that the release of the drug from nanodevice depends on the concentration of the drug. 
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Figure 43. Drug release profile of G4-OH-link-allopregnanolone nanodevice at pH 2.1. 
4.5 Discussion  
TBI is a significant public health problem throughout the world. It can cause cerebral 
edema, inflammation, tissue necrosis, programmed cell death, etc. The research findings have 
shown that the progesterone may be a promising therapeutic drug for the treatment of TBI. 
Progesterone belongs to the group of neurosteroids. It has a variety of neurprotective roles during 
gestation, and it has also been linked to several different modes of neuroprotection following 
TBI, including the attenuation of cerebral edema, the reduction of lipid peroxidation and 
oxidative stress, anti-inflammatory effects, reduction of cellular apoptosis, inhibition of 
excitotoxicity, and assisting in the repair of myelin. However, the poor aqueous solubility of 
progesterone limits its potential use as a therapeutic. It is known that the protective effects of 
progesterone in the brain arise largely from its conversion to 5α-reduced metabolites such as 
allopregnanolone (5α -pregnane-3α ol, 20-one or 5α -tetrahydroprogesterone). Allopregnanolone 
binds to a steroid-binding site on the GABAA receptor complex, and by increasing chloride flux 
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thereby increase GABAergic receptor activity and decrease the excitability of the central nervous 
system.  
In this study allopregnanolone and allopregnanolone isomer were conjugated to 
generation 4 hydroxyl PAMAM dendrimer as a drug carrier with a longer and shorter spacer 
respectively.  Since release study of G4-OH-allopregnanolone isomer at pH 7.4, 4.6, and 2.1 
showed no drug release from conjugate, allopregnanolone was reacted first to succinic anhydride 
to obtaine an acid group required for conjugation raction with the dendrimer and then conjugated 
to bifuctional dendrimer that is G4-OH dendrimer having several linker moieties terminated with 
amine groups. The spacer between drug and dendrimer had a peptide link and because it was 
longer moved drug molecules a little bit further from dendrimer reducing the steric effect and 
resulted in effective drug release in acidic conditions. Around 90% of allopregnanolone was 
successfully released in 9 days from the dendrimer-drug nanodevice at 2.1 pH. Future study will 
involve in vitro determination of pharmacological activity of dendrimer-allopregnanolone 
nanodevices, by measuring the inhibition of prostaglandin secretion in LPS pretreated A 549 
lung epithelial cells. 
4.6 Future Work 
4.6.1 Pharmacological Activity of Dendrimer-Allopregnanolone Nanodevice  
Prostaglandins (PGs) play a key role in the generation of the inflammatory response. 
Their concentration is elevated in inflamed tissue and can lead to acute inflammation. To 
evaluate the therapeutic potential of dendrimer-allopregnanolone nanodevices, in inhibiting the 
prostaglandin synthesis, an in vitro study can be demonstrated using A549 human lung epithelial 
carcinoma cell lines. The pretreated cells with lipopolysaccharide induce prostaglandin synthesis. 
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The inhibition of prostaglandin synthesis by dendrimer-allopregnanolone nanodevices would be 
the measure of anti-inflammatory activity of the nanodevices. 
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APPENDIX 
Selected 1H ans ESI MS Spectra 
 
 
 
 
 
 
 
 
 
89 
 
 
Proton NMR of 5β Reduction Product 
 
  
ESI MS of of 5β Reduction Product, 
(m/z): calc. for C21H32O2 [M+H]+ 317.2481, found 317.2471 
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Proton NMR of Allopregnanolone Isomer. 
 
 
ESI MS Allopregnanolone Isomer 
(m/z): calc. for C21H35O2 [M+H]+ 319.2637, found 319.2630 
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Proton NMR of Allopregnanolone Isomer Succinate. 
 
ESI MS of Allopregnanolone Isomer Succinate 
(m/z): calc. for C21H37O5 [M-H]+ 417.2641, found 417.2652 
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Proton NMR of Allopregnanolone Succinate 
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ABSTRACT 
PAMAM DENDRIMER-BASED THERAPEUTIC AND DIAGNOSTIC NANODEVICES 
by 
ADMIRA BOSNJAKOVIC  
December 2011 
Advisor: Dr. Rangaramanujam M. Kannan 
Major: Materials Science and Engineering 
Degree: Doctor of Philosophy 
Dendrimers are ideal materials to be used in the emerging field of nanomedicine. Their 
nanoscale size and high density of functional groups on their peripheries allow them to be used 
for various biomedical applications. This work exploits dendrimers as drug delivery vehicles and 
a versatile platform for capturing biomarkers with improved sensitivity and specificity. Hydroxyl 
terminated poly(amidoamine) dendrimer (PAMAM-OH) was modified with a linker having 
amine group at the end and conjugated to two drugs, erythromycin (EM) and allopregnanonolne, 
respectively and evaluated in vitro.  Both drugs were provided with a linker having carboxylic 
group required for conjugation reaction with dendrimer. The release rate of the drugs from the 
conjugates in PBS buffers at pH 7.4 for EM and pH 2.1 for allopregnanolone were evaluated by 
reverse phase HPLC (RP-HPLC) analysis. EM released quite fast, about 90% of the drug was 
released within 10 hours and completed within 20 hours, while allopregnanolone released in 
slower manner, about 90% of the drug was released within 9 days. Dendrimer-EM conjugate was 
not cytotoxic and was significantly efficacious in inhibiting the nitrite production compared to 
free drug. The inhibition of bacterial growth by dendrimer-EM conjugate was comparable to free 
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EM. Combined with the intinsinic properties of dendrimers, these nanodevices could lead to 
improved in vivo efficacy. PAMAM-OH was successfully used for the development of a solid 
phase bio-sensing platform. The ELISA plate was modified first with polyethylene-glycol (PEG) 
and then PAMAM-OH was immobilized.  A capture antibody was oxidized and covalently 
attached to dendrimer-modified ELISA plate which gives antibody favorable orientation for the 
antigen binding sites toward the analyte. The dendrimer modified plate showed enhanced 
sensitivity and the detection limit for TNF-α was found to be 0.48 pg/mL, which is significantly 
better than the commercially available ELISA kit. The selectivity of the dendrimer-modified 
ELISA plate was examined by studying TNF-α in a mixture of cytokines which gave similar 
results. Dendrimer-modified ELISA plate provides a greater opportunity for the detection of a 
wide range of cytokines and biomarkers.  
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